Current Size: 100%

Publications

Peer Reviewed Publications since 2006

NOTE: This list contains only peer-reviewed papers, other publications can be obtained via the project leaders.

 

Publications 2015

Andric T, Weiss TW, Huber K, Arnesen H, Seljeflot I. Effects of diet and/or n-3 fatty acid supplementation on components of the interleukin-6 trans-signalling system in elderly men. Scand J Clin Lab Invest. 2015;75:646-51. IF: 1.989

Aradi D, Collet JP, Mair J, Plebani M, Merkely B, Jaffe AS, Möckel M, Giannitsis E, Thygesen K, ten Berg JM, Mueller C, Storey RF, Lindahl B, Huber K;  Study Group on Biomarkers in Cardiology of the Acute Cardiovascular Care Association of the European Society of Cardiology; Working Group on Thrombosis of the European Society of Cardiology. Platelet function testing in acute cardiac care - is there a role for prediction or prevention of stent thrombosis and bleeding? Thromb Haemost. 2015;113:221-30. IF: 4.984

Bergmeister H, Seyidova N, Schreiber C, Strobl MGrasl C, Walter I, Messner B, Baudis S, Fröhlich S, Marchetti-Deschmann M, Griesser M, di Franco M, Krssak M, Liska R, Schima H.  Biodegradable, thermoplastic polyurethane grafts for small diameter vascular replacements. Acta Biomater. 2015;11:104-13. IF: 6.025

Freynhofer MK, Gruber SC, Grove EL, Weiss TW, Wojta JHuber K. Antiplatelet drugs in patients with enhanced platelet turnover: biomarkers versus platelet function testing. Thromb Haemost. 2015;114:459-68. IF: 4.984

Granegger M, Masetti M, Laohasurayodhin RSchloglhofer T, Zimpfer D, Schima HMoscato F. Continuous monitoring of aortic valve opening in rotary blood pump patients. IEEE Trans Biomed Eng. 2015 Oct 9. [Epub ahead of print] PubMed PMID: 26461795. IF: 2.347

Gyöngyösi M, Wojakowski W, Lemarchand P, Lunde K, Tendera M, Bartunek J, Marban E, Assmus A, Henry TD, Traverse JH, Moyé LA, Sürder D, Corti R, Huikuri H, Miettinen J, Wöhrle J, Obradovic S, Roncalli J, Malliaras K, Pokushalov E, Romanov A, Kastrup J, Bergmann MW, Atsma DE, Diederichsen A, Edes I, Benedek I, Benedek T, Pejkov H, Nyolczas N, Pavo N, Bergler-Klein J, Pavo IJ, Sylven C, Berti S, Navarese EP, Maurer G, for the ACCRUE investigators. Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data. Circ Res. 2015;116:1346-60. IF:

Hayward C, Lim CP, Schima H, Macdonald P, Moscato F, Muthiah K, Granegger M. Pump Speed Waveform Analysis to Detect Aortic Valve Opening in Patients on Ventricular Assist Device Support. Artif Organs. 2015;39:704-9. IF: 2.05

Huber K. Prasugrel in clopidogrel nonresponders: a way to improve secondary prevention in patients after percutaneous coronary intervention? JACC Cardiovasc Interv. 2015;8:1571-3. IF: 7.345

Jäger B, Farhan S, Kalla K, Glogar HD, Christ G, Karnik R, Norman G, Prachar H, Schreiber W, Kaff A, Podczeck-Schweighofer A, Weidinger F, Stefenelli T, Delle-Karth G, Laggner AN, Maurer G, Huber K; Vienna STEMI Registry Group. One-year mortality in patients with acute ST-elevation myocardial infarction in the Vienna STEMI registry. Wien Klin Wochenschr. 2015;127:535-42. IF: 0.836

Katsaros KM, Speidl WS, Demyanets S, Kastl SPKrychtiuk KA, Wonnerth A, Zorn G, Tentzeris I, Farhan S, Maurer G, Wojta JHuber K. G-CSF predicts cardiovascular events in patients with stable coronary artery disease. PLoS One. 2015;10:e0142532. IF: 3.234

Kozarov E, Huber KWojta J. Infection-associated biomarkers of inflammation in atherosclerosis. Curr Pharm Des. 2015;21:1776-82. IF: 3.452

Krychtiuk KA, Kastl SP, Hofbauer SL, Wonnerth A, Goliasch G, Ozsvar-Kozma M, Katsaros KM, Maurer G, Huber K, Dostal E, Binder CJ, Pfaffenberger S, Oravec S, Wojta J, Speidl WS. Monocyte subset distribution in patients with stable atherosclerosis and elevated levels of lipoprotein(a). J Clin Lipidol. 2015;9:533-41. IF: 3.904

Krychtiuk KA, Kastl SP, Pfaffenberger S, Lenz M, Hofbauer SL, Wonnerth A, Koller L, Katsaros KM, Pongratz T, Goliasch G, Niessner A, Gaspar L, Huber K, Maurer G, Dostal E, Wojta J, Oravec S, Speidl WS. Association of small dense LDL serum levels and circulating monocyte subsets in stable coronary artery disease. PLoS One. 2015;10:e0123367. IF: 3.234

Krychtiuk KA, Ruhittel S, Hohensinner PJ, Koller L, Kaun C, Lenz M, Bauer B, Wutzlhofer L, Draxler DF, Maurer G, Huber KWojta J, Heinz G, Niessner A, Speidl WS. Mitochondrial DNA and toll-like receptor-9 are associated with mortality in critically ill Patients. Crit Care Med. 2015;43:2633-41. IF: 6.312

Krychtiuk KA, Watzke L, Kaun C, Buchberger E, Hofer-Warbinek R, Demyanets S, Pisoni J, Kastl SP, Rauscher S, Gröger M, Aliabadi A, Zuckermann A, Maurer G, de Martin R, Huber KWojta J, Speidl WS. Levosimendan exerts anti-inflammatory effects on cardiac myocytes and endothelial cells in vitro. Thromb Haemost. 2015;113:350-62. IF: 4.984

Mazza G, Stoiber M, Pfeiffer D, Schima H. Atraumatic Pulsatile Leukocyte Circulation for Long-Term In Vitro Dynamic Culture and Adhesion Assays. Artif Organs. 2015;39:973-8. IF: 2050

Rohla M, Vennekate CK, Tentzeris I, Freynhofer MK, Farhan S, Egger F, Weiss TW, Wojta J, Granger CB, Huber K. Long-term mortality of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation for acute and stable coronary artery disease. Int J Cardiol. 2015;184:108-14. IF: 4.036

Santer DNagel F, Kreibich M, Dzilic E, Moser PT, Muschitz G, Inci M, Krssak M, Plasenzotti P, Bergmeister HTrescher KPodesser BK. In vivo and ex vivo functional characterization of left ventricular remodelling after myocardial infarction in mice. ESC Heart Failure. 2015;2:171-177.

Schrör K, Huber K. Platelets, inflammation and anti-inflammatory drugs in ACS and CAD. Thromb Haemost. 2015;114:446-8. IF: 4.984

Siller-Matula JM, Trenk D, Schrör K, Gawaz M, Kristensen SD, Storey RF, Huber K; European Platelet Academy. How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors--is an algorithm the answer? Thromb Haemost. 2015;113:37-52. IF: 4.984

Stoiber M, Messner B, Grasl C, Gschlad V, Bergmeister H, Bernhard D, Schima H. A method for mechanical characterization of small blood vessels and vascular grafts. Experimental Mechanics. 2015; 55:1591–1595. IF: 1.548

Stojkovic S, Ristl R, Moser FT, Wolzt M, Wojta J, Schmidinger H, Pezawas T. T-wave variability for the prediction of fast ventricular arrhythmias – prospective, observer-blind study. Circ J. 2015;79:318-24. IF: 3.940

Trescher K, Dzilic E, Kreibich M, Gasser H, Aumayr K, Kerjaschki D, Pelzmann B, Hallström S, Podesser BK. The nitric oxide donor, S-nitroso human serum albumin, as an adjunct to HTK-N cardioplegia improves protection during cardioplegic arrest after myocardial infarction in rats. Interact Cardiovasc Thorac Surg. 2015;20:387-94. IF: 1.155

Wojta J. Platelet-derived microparticles in patients with high cardiovascular risk and subclinical atherosclerosis. Thromb Haemost. 2015;114:1099. IF: 4.984

 

Publications 2014

Adlbrecht C, Huber K, Reynolds HR, Carvalho AC, Džavík V, Steg PG, Liu L, Marino P, Pearte CA, Rankin JM, White HD, Lamas GA, Hochman JS. Effects of timing, location and definition of reinfarction on mortality in patients with totally occluded infarct related arteries late after myocardial infarction. Int J Cardiol. 2014 Jun 1;174(1):90-5. TOP 10% IF 6.175

Demyanets S, Speidl WS, Tentzeris I, Jarai R, Katsaros KM, Farhan S, Krychtiuk KA, Wonnerth A, Weiss TW, Huber KWojta J. Soluble ST2 and interleukin-33 levels in coronary artery disease: relation to disease activity and adverse outcome. PLoS One. 2014 Apr 21;9(4):e95055. IF 3.534

Demyanets S, Tentzeris I, Jarai R, Katsaros KM, Farhan S, Wonnerth A, Weiss TW, Wojta J, Speidl WS, Huber K. An increase of interleukin-33 serum levels after coronary stent implantation is associated with coronary in-stent restenosis. Cytokine. 2014 Jun;67(2):65-70. IF 2.847

Egger F, Nürnberg M, Rohla M, Weiss TW, Unger G, Smetana P, Geppert A, Gruber SC, Bambazek A, Falkensammer J, Waldenberger FR, Huber KFreynhofer MK. High-degree atrioventricular block in patients with preexisting bundle branch block or bundle branch block occurring during transcatheter aortic valve implantation. Heart Rhythm. 2014 Dec;11(12):2176-82. IF 4.918

Freynhofer MK, Bruno V, Brozovic I, Jarai R, Vogel B, Farhan S, Hübl W, Willheim M, Wojta JHuber K. Variability of on-treatment platelet reactivity in patients on clopidogrel. Platelets. 2014;25(5):328-36. IF 2.627

Granegger MSchima H, Zimpfer D, Moscato F. Assessment of aortic valve opening during rotary blood pump support using pump signals. Artif Organs. 2014 Apr;38(4):290-7. IF 1.870 Schima HStoiber MSchlöglhofer T, Hartner Z, Haberl T, Zimpfer D. Repair of left ventricular assist device driveline damage directly at the transcutaneous exit site. Artif Organs. 2014 May;38(5):422-5. IF 1.870

Halvorsen S, Huber K. Fibrinolytic treatment of ST-elevation myocardial infarction. Update 2014. Hamostaseologie. 2014 Feb 4;34(1):47-53. IF 1.589

Höchtl T, Huber K. P2Y12-receptor-inhibiting antiplatelet strategies in acute coronary syndromes. Hamostaseologie. 2014 Feb 4;34(1):20-8. IF 1.589

Höchtl-Hainzl T, Huber K. Direct anticoagulants for atrial fibrillation. Update 2014. Herz. 2014 May;39(3):357-67. IF 0.912

Juraszek A, Dziodzio T, Stoiber M, Fechtig D, Gschlad V, Aigner P, Czerny M, Schima H. The influence of bicuspid aortic valves on the dynamic pressure distribution in the ascending aorta: a porcine ex vivo model. Eur J Cardiothorac Surg. 2014 Sep;46(3):349-55; discussion 355. IF 3.048

Katsaros KM, Kastl SP, Krychtiuk KA, Hutter R, Zorn G, Maurer G, Huber K, Wojta J, Christ G, Speidl WS. An increase of VEGF plasma levels is associated with restenosis of drug-eluting stents. EuroIntervention. 2014 Jun;10(2):224-30. IF 3.758

Krychtiuk KA, Kastl SP, Pfaffenberger S, Pongratz T, Hofbauer SL, Wonnerth A, Katsaros KM, Goliasch G, Gaspar L, Huber K, Maurer G, Dostal E, Oravec S, Wojta J, Speidl WS. Small high-density lipoprotein is associated with monocyte subsets in stable coronary artery disease. Atherosclerosis. 2014 Dec;237(2):589-96. IF 3.991

Krychtiuk KA, Nürnberg M, Volker R, Pachinger L, Jarai R, Freynhofer MKWojta JHuber K, Weiss TW. Effects of AV-delay optimization on hemodynamic parameters in patients with VDD pacemakers. Wien Klin Wochenschr. 2014 May;126(9-10):270-7. IF 0.791

Moscato FGranegger M, Edelmayer M, Zimpfer D, Schima H. Continuous monitoring of cardiac rhythms in left ventricular assist device patients. Artif Organs. 2014 Mar;38(3):191-8. IF 1.870

Pavo N, Charwat S, Nyolczas N, Jakab A, Murlasits Z, Bergler-Klein J, Nikfardjam M, Benedek I, Benedek T, Pavo IJ, Gersh BJ, Huber K, Maurer G, Gyöngyösi M. Cell therapy for human ischemic heart diseases: critical review and summary of the clinical experiences. J Mol Cell Cardiol. 2014 Oct;75:12-24. IF 5.218

Rohla M, Freynhofer MK, Hammerl H, Weiss TW, Huber K. Stroke and recurrent left atrial appendage thrombus in a patient with atrial fibrillation under old and new oral anticoagulants: a case report. Thromb Haemost. 2014 Feb;111(2):375-8. IF 5.760

Rohla M, Freynhofer MK, Tentzeris I, Farhan S, Wojta JHuber K, Weiss TW. Plasma osmolality predicts clinical outcome in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Eur Heart J Acute Cardiovasc Care. 2014 Mar;3(1):84-92. IF 0

Schima H, Zrunek P, Stoiber M, Larose J, Shambaugh C, Tamez D, Deckert Z, Plasenzotti R, Bergmeister H, Wieselthaler G. Extended in vivo evaluation of a miniaturized axial flow pump with a novel inflow cannula for a minimal invasive implantation procedure. J Heart Lung Transplant. 2014 Apr;33(4):422-8. IF 5.611

Schima HSchlöglhofer T, zu Dohna R, Drews T, Morshuis M, Roefe D, Schmitto JD, Strüber M, Zimpfer D. Usability of ventricular assist devices in daily experience: a multicenter study. Artif Organs. 2014 Sep;38(9):751-60. IF 1.870

Schlöglhofer T, Gilly H, Schima H. Semi-invasive measurement of cardiac output based on pulse contour: a review and analysis. Can J Anaesth. 2014 May;61(5):452-79. IF 2.495

Sherif C, Kleinpeter G, Mach G, Loyoddin M, Haider T, Plasenzotti R, Bergmeister H, Di Ieva A, Gibson D, Krssak M. Evaluation of cerebral aneurysm wall thickness in experimental aneurysms: comparison of 3T-MR imaging with direct microscopic measurements. Acta Neurochir (Wien). 2014 Jan;156(1):27-34. IF 1.788

Stojkovic S, Kaun C, Heinz M, Krychtiuk KA, Rauscher S, Lemberger CE, de Martin R, Gröger M, Petzelbauer P, Huk I, Huber K, Wojta J, Demyanets S. Interleukin-33 induces urokinase in human endothelial cells--possible impact on angiogenesis. J Thromb Haemost. 2014 Jun;12(6):948-57. IF 5.550

Tentzeris I, Rohla M, Jarai R, Farhan S, Freynhofer MK, Unger G, Nürnberg M, Geppert A, Wessely E, Wojta JHuber K. Influence of high-dose highly efficient statins on short-term mortality in patients undergoing percutaneous coronary intervention with stenting for acute coronary syndromes. Am J Cardiol. 2014 Apr 1;113(7):1099-104. IF 3.425

Trescher K, Hasun M, Baumgartner A, Dietl W, Wolfsberger M, Hallström S, Podesser BK. New HTK-N46B cardioplegia provides superior protection during ischemia/reperfusion in failing hearts. J Cardiovasc Surg (Torino). 2013 J;54:413-21. IF: 1.510

Trescher K, Thometich B, Demyanets S, Kassal H, Sedivy R, Bittner R, Holzinger C, Podesser BK. Type A dissection and chronic dilatation: tenascin-C as a key factor in destabilization of the aortic wall. Interact Cardiovasc Thorac Surg. 2013;17:365-70. IF: 1.112

Wonnerth A, Katsaros KM, Krychtiuk KA, Speidl WS, Kaun C, Thaler K, Huber KWojta J, Maurer G, Seljeflot I, Arnesen H, Weiss TW. Glycoprotein 130 polymorphism predicts soluble glycoprotein 130 levels. Metabolism. 2014 May;63(5):647-53. IF 0

 

Publications 2013

Aigner P, Eskandary F, Schlöglhofer T, Gottardi R, Aumayr K, Laufer G, Schima H. Sternal force distribution during median sternotomy retraction. J Thorac Cardiovasc Surg. 2013;146:1381-6. IF: 3.526

Alessi MC, Wojta J. Obesity and vascular disease: from bench to bedside. Thromb Haemost. 2013;110:632-3. IF: 6.094

Bergmeister H, Schreiber C, Grasl C, Walter I, Plasenzotti R, Stoiber M, Bernhard D, Schima H. Healing characteristics of electrospun polyurethane grafts with various porosities. Acta Biomater. 2013;9:6032-40. IF: 5.093

Bergmeister H, Strobl M, Grasl C, Liska R, Schima H. Tissue engineering of vascular grafts. Eur Surg 2013;45:187-193. IF: 0.148

Demyanets S, Kaun C, Pentz R, Krychtiuk KA, Rauscher S, Pfaffenberger S, Zuckermann A, Aliabadi A, Gröger M, Maurer G, Huber K, Wojta J. Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature. J Mol Cell Cardiol. 2013;60:16-26. IF: 5.148

Emmert MY, Wolint P, Winklhofer S, Stolzmann P, Cesarovic N, Fleischmann T, Nguyen TD, Frauenfelder T, Böni R, Scherman J, Bettex D, Grünenfelder J, Schwartlander R, Vogel V, Gyöngyösi M*, Alkadhi H, Falk V, Hoerstrup SP. Transcatheter based electromechanical mapping guided intramyocardial transplantation and in vivo tracking of human stem cell based three dimensional microtissues in the porcine heart. Biomaterials. 2013;34:2428-41. IF: 7.4 (*Leader of MUW Project)

Freynhofer MK, Bruno V, Brozovic I, Jarai R, Vogel B, Farhan S, Hübl W, Willheim M, Wojta J, Huber K. Variability of on-treatment platelet reactivity in patients on clopidogrel. Platelets. 2013. [Epub ahead of print] IF: 2.240

Freynhofer MK, Draxler DF, Gruber SC, Bruno V, Höchtl T, Fellner B, Jakl-Kotauschek G, Wojta J, Pabinger-Fasching I, Huber K, Ay C. Endogenous t-PA- antigen is an independent predictor of adverse cardiovascular events and all-cause death in patients with atrial fibrillation. J Thromb Haemost. 2013;11:1069-77. IF: 6.081

Freynhofer MK, Gruber SC, Bruno V, Höchtl T, Farhan S, Zaller V, Wojta J, Huber K. Prognostic value of plasma von Willebrand factor and its cleaving protease ADAMTS13 in patients with atrial fibrillation. Int J Cardiol. 2013;168:317-25. IF: 5.509

Granegger M, Mahr S, Horvat J, Aigner P, Roehrich M, Stoiber M, Plasenzotti R, Zimpfer D, Schima H, Moscato F. Investigation of hemodynamics in the assisted isolated porcine heart. Int J Artif Organs. 2013;36:878-86. IF: 1.759

Grasl C., Arras MM, Stoiber M, Bergmeister H., Schima H., Electrodynamic control of the nanofiber alignment during electrospinning. Applied Physics Letters, 2013;102:053111. IF: 3.794

Krychtiuk KA, Kastl SP, Speidl WS, Wojta J. Inflammation and coagulation in atherosclerosis. Hamostaseologie. 2013;33:269-82. IF: 1.479

Mashayekhi R, Mobedi H, Najafi J, Enayati M., In-vitro/In-vivo comparison of leuprolide release from an in-situ forming plga system, DARU J Pharmt Sci, 2013;21:57 -64. IF:0.620

Moscato F, Wirrmann C, Granegger M, Eskandary F, Zimpfer D, Schima H. Use of continuous flow ventricular assist devices in patients with heart failure and a normal ejection fraction: a computer-simulation study. J Thorac Cardiovasc Surg. 2013;145:1352-8. IF: 3.526

Pfaffenberger S, Vyskocil E, Kollmann C, Unger E, Kaun C, Kastl S, Woeber C, Nawratil G, Huber K, Maurer G, Gottsauner-Wolf M, Wojta J. Transtemporal ultrasound application potentially elevates brain temperature: results of an anthropomorphic skull model. Ultraschall Med. 2013;34:51-7. IF: 4.116

Rega-Kaun G, Kaun C, Wojta J. More than a simple storage organ: adipose tissue as a source of adipokines involved in cardiovascular disease. Thromb Haemost. 2013;110:641-50. IF: 6.094

Schima H, Schlöglhofer T, Hartner Z, Horvat J, Zimpfer D. Importance of linguistic details in alarm messages of ventricular assist devices. Int J Artif Organs. 2013;36:406-9. IF: 1.759

Schlöglhofer T, Aigner P, Stoiber M, Schima H. Fixation and mounting of porcine aortic valves for use in mock circuits. Int J Artif Organs. 2013;36:738-41. IF: 1.759

Sherif C, Kleinpeter G, Mach G, Loyoddin M, Haider T, Plasenzotti R, Bergmeister H, Di Ieva A, Gibson D, Krssak M. Evaluation of cerebral aneurysm wall thickness in experimental aneurysms: comparison of 3T-MR imaging with direct microscopic measurements. Acta Neurochir (Wien). 2014;156:27-34. IF: 1.546

Siller-Matula JM, Trenk D, Schrör K, Gawaz M, Kristensen SD, Storey RF, Huber K; EPA (European Platelet Academy). Response variability to P2Y12 receptor inhibitors: expectations and reality. JACC Cardiovasc Interv. 2013;6:1111-28. IF: 6.552

Stoiber M, Schlöglhofer T, Aigner P, Grasl C, Schima H. An alternative method to create highly transparent hollow models for flow visualization. Int J Artif Organs. 2013;36(2):131-4. IF: 1.75

Strobl M, Schreiber C, Panzenböck A, Winter MP, Bergmeister H, Jakowitsch J, Mascherbauer J, Lang IM, Wexberg P, Bonderman D. Exhaled nitric oxide measurement to monitor pulmonary hypertension in a pneumonectomy-monocrotaline rat model. Am J Physiol Lung Cell Mol Physiol. 2013;305:L485-90. IF: 3.523

Trescher K, Hasun M, Baumgartner A, Dietl W, Wolfsberger M, Hallström S, Podesser BK. New HTK-N46B cardioplegia provides superior protection during ischemia/reperfusion in failing hearts. J Cardiovasc Surg (Torino). 2013 J;54:413-21. IF: 1.510

Trescher K, Thometich B, Demyanets S, Kassal H, Sedivy R, Bittner R, Holzinger C, Podesser BK. Type A dissection and chronic dilatation: tenascin-C as a key factor in destabilization of the aortic wall. Interact Cardiovasc Thorac Surg. 2013;17:365-70. IF: 1.112

 

 

Publications 2012

Alfonso F, Timmis A, Pinto FJ, Ambrosio G, Ector H, Kulakowski P, Vardas P; Editors' Network European Society of Cardiology Task Force, Antoniades L, Ahmad M, Apetrei E, Arai K, Artigou JY, Aschermann M, Böhm M, Bolognese L, Bugiardini R, Cohen A, Edes I, Elias J, Galeano J, Guarda E, Haouala H, Heras M, Höglund C, Huber K, Hulin I, Ivanusa M, Krittayaphong R, Kuo CT, Lau CP, Lyusov VA, Marinskis G, Márquez MF, Masic I, Moreira LF, Mrochek A, Oganov RG, Raev D, Rogava M, Rødevand O, Sansoy V, Shimokawa H, Shumakov VA, Tajer CD, van der Wall EE, Stefanadis C, Videbæk J, Lüscher TF. Conflict of interest policies and disclosure requirements among European Society of Cardiology national cardiovascular journals. Heart. 2012 Apr;98(7):e1-7.

Angiolillo DJ, Schneider DJ, Bhatt DL, French WJ, Price MJ, Saucedo JF,
Shaburishvili T, Huber K, Prats J, Liu T, Harrington RA, Becker RC.
Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. J Thromb Thrombolysis. 2012 in press.

Arras M, Grasl C, Bergmeister H, Schima H. Generation of aligned electrospun fibres with adjustable orientation angles by using auxiliary electrodes. Sci Technol Adv Mat. 2012; in press.

Bergmeister H, Grasl C, Walter I, Plasenzotti R, Stoiber M, Schreiber C, Losert U, Weigel G, Schima H. Electrospun small-diameter polyurethane vascular grafts: ingrowth and differentiation of vascular-specific host cells. Artif Organs. 2012;36:54-

Coordinating Committee, De Caterina R, Husted S, Wallentin L, De Caterina R,
Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Huber K, Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Siegbahn A,
Verheugt FW, Weitz JI. New Oral Anticoagulants in Atrial Fibrillation and Acute
Coronary Syndromes: ESC Working Group on Thrombosis-Task Force on
Anticoagulants in Heart Disease Position Paper. J Am Coll Cardiol. 2012;59:1413-25.

Demyanets S, Huber K, Wojta J. Vascular effects of glycoprotein130 ligands - part I: pathophysiological role. Vascul Pharmacol. 2012;56:34-46.

Demyanets S, Huber K, Wojta J. Vascular effects of glycoprotein130 ligands - part II: Biomarkers and therapeutic targets. Vascul Pharmacol. 2012: in press.

Farhan S, Jarai R, Tentzeris I, Kautzky-Willer A, Samaha E, Smetana P, Jakl-
Kotauschek G, Wojta J, Huber K. Comparison of HbA1c and oral glucose tolerancetest for diagnosis of diabetes in patients with coronary artery disease. Clin Res Cardiol. 2012: in press.

Farhan S, Tentzeris I, Freynhofer MK, Vogel B, Huber K. Antithrombotic therapy in patients with acute coronary syndrome and diabetes mellitus. Herz. 2012;3:264-272.

Farhan S, Jarai R, Tentzeris I, Kautzky-Willer A, Samaha E, Smetana P, Jakl-
Kotauschek G, Wojta J, Huber K. Comparison of HbA1c and oral glucose tolerance test for diagnosis of diabetes in patients with coronary artery disease. Clin Res Cardiol. 2012 in press.

Farhan S, Handisurya A, Todoric J, Tura A, Pacini G, Wagner O, Klein K, Jarai
R, Huber K, Kautzky-Willer A. Fetuin-A Characteristics during and after pregnancy: Result from a case control pilot study. Int J Endocrinol. 2012 in press.

Freynhofer MK, Bruno V, Willheim M, Hübl W, Wojta J, Huber K. Vasodilatorstimulated phosphoprotein-phosphorylation assay in patients on clopidogrel: does standardisation matter? Thromb Haemost. 2012;107:538-44.

Goliasch G, Oravec S, Blessberger H, Dostal E, Hoke M, Wojta J, Schillinger M,
Huber K, Maurer G, Wiesbauer F. Relative importance of different lipid risk factors for the development of myocardial infarction at a very young age (<40 years of age). Eur J Clin Invest. 2012;42:631-6

Goliasch G, Wiesbauer F, Kastl SP, Katsaros KM, Blessberger H, Maurer G,
Schillinger M, Huber K, Wojta J, Speidl WS. Premature myocardial infarction is
associated with low serum levels of Wnt-1. Atherosclerosis. 2012;222:251-6.

Goliasch G, Haschemi A, Marculescu R, Endler G, Maurer G, Wagner O,
Huber K, Mannhalter C, Niessner A. Butyrylcholinesterase activity predicts long-term survival in patients with coronary artery disease. Clin Chem. 2012 in press.

Granegger M, Moscato F, Casas F, Wieselthaler G, Schima H. Development of a pump flow estimator for rotary blood pumps to enhance monitoring of ventricular function. Artif Organs 2012: in press.

Heberlein KR, Han J, Straub AC, Best AK, Kaun C, Wojta J, Isakson BE. A novel
mRNA binding protein complex promotes localized plasminogen activator inhibitor-1 18 accumulation at the myoendothelial junction. Arterioscler Thromb Vasc Biol. 2012;32:1271-9.

Höchtl T, Huber K. New anticoagulants for the prevention of stroke in atrial fibrillation. Fundam Clin Pharmacol. 2012;26:47-53.

Janata K, Höchtl T, Wenzel C, Jarai R, Fellner B, Geppert A, Smetana P, Havranek V, Huber K. The role of ST-segment elevation in lead aVR in the risk assessment of patients with acute pulmonary embolism. Clin Res Cardiol. 2012;101:329-37.

Kristensen SD, Würtz M, Grove EL, De Caterina R, Huber K, Moliterno DJ, Neumann FJ. Contemporary use of glycoprotein IIb/IIIa inhibitors. Thromb Haemost. 2012;107:215-24.

Moscato F, Granegger M, Naiyanetr P, Wieselthaler G, Schima H. Evaluation of left ventricular relaxation in rotary blood pump recipients using the pump flow waveform: a simulation study. Artif Organs. 2012;36:470-8.

Pamukcu B, Huber K, Lip GY. Antiplatelet therapy in atherothrombotic cardiovascular diseases for primary and secondary prevention: a focus on old and new antiplatelet agents. Curr Pharm Des. 2012;18:850-60.

Plass CA, Loew HG, Podesser BK, Prusa AM. Light-induced vasodilation of coronary arteries and its possible clinical implication. Ann Thorac Surg. 2012;93:1181-6.

Richter B, Gwechenberger M, Socas A, Zorn G, Albinni S, Marx M, Bergler-Klein J, Binder T, Wojta J, Gössinger HD. Markers of oxidative stress after ablation of atrial fibrillation are associated with inflammation, delivered radiofrequency energy and early recurrence of atrial fibrillation. Clin Res Cardiol. 2012;101:217-25.

Rubboli A, Dewilde W, Huber K, Eeckhout E, Herzfeld I, Valencia J, Windecker S,
Airaksinen KE, Lip GY. The management of patients on oral anticoagulation
undergoing coronary stent implantation: a survey among interventional cardiologists from eight European countries. J Interv Cardiol. 2012;25:163-9.

Saely CH, Rein P, Vonbank A, Huber K, Drexel H. Type 2 diabetes and the
progression of visualized atherosclerosis to clinical cardiovascular events. Int J
Cardiol. 2012 in press.

Schrör K, Siller-Matula JM, Huber K. Pharmacokinetic basis of the antiplatelet action of prasugrel. Fundam Clin Pharmacol. 2012;26:39-46.

Siller-Matula JM, Delle-Karth G, Lang IM, Neunteufl T, Kozinski M, Kubica J, Maurer G, Linkowska K, Grzybowski T, Huber K, Jilma B. Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study. J Thromb Haemost. 2012;10:529-42.

Siller-Matula JM, Delle-Karth G, Christ G, Neunteufl T, Maurer G, Huber K,
Tolios A, Drucker C, Jilma B. Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin. Int J Cardiol. 2012 in press.

Silvain J, Beygui F, Barthélémy O, Pollack C Jr, Cohen M, Zeymer U, Huber K,
Goldstein P, Cayla G, Collet JP, Vicaut E, Montalescot G. Efficacy and safety of
enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. BMJ. 2012;344:e553.

Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F, White HD, Aylward PE, Wallentin L, Chen E, Lokhnygina Y, Pei J, Leonardi S, Rorick TL, Kilian AM, Jennings LH, Ambrosio G, Bode C, Cequier A, Cornel JH, Diaz R, Erkan A, Huber K, Hudson MP, Jiang L, Jukema JW, Lewis BS, Lincoff AM, Montalescot G, Nicolau JC, Ogawa H, Pfisterer M, Prieto JC, Ruzyllo W, Sinnaeve PR, Storey RF, Valgimigli M, Whellan DJ, Widimsky P, Strony J, Harrington RA, Mahaffey KW; TRACER Investigators. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med. 2012;366:20-33.

Zeymer U, Arntz HR, Mark B, Fichtlscherer S, Werner G, Schöller R, Zahn R, Diller F, Darius H, Dill T, Huber K. Efficacy and safety of a high loading dose of clopidogrel administered prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomized CIPAMI trial. Clin Res Cardiol. 2012;101:305-12.

 

Publications 2011

Baudis S, Nehl F, Ligon SC, Nigisch A, Bergmeister H, Bernhard D, Stampfl J, Liska R. Elastomeric degradable biomaterials by photopolymerization-based CAD-CAM for vascular tissue engineering. Biomed Mater. 2011;6:055003.

Dziodzio T, Juraszek A, Reineke D, Jenni H, Zermatten E, Zimpfer D, Stoiber M,
Scheikl V, Schima H, Grimm M, Czerny M. Experimental acute type B aortic dissection: different sites of primary entry tears cause different ways of propagation. Ann Thorac Surg. 2011;91:724-7.

Filipovic N, Schima H. Numerical simulation of the flow field within the aortic arch during cardiac assist. Artif Organs. 2011;35:E73-83.

Geidl L, Deckert Z, Zrunek P, Gottardi R, Sterz F, Wieselthaler G, Schima H. Intuitive use and usability of ventricular assist device peripheral components in simulated emergency conditions. Artif Organs. 2011;35:773-80.

Demyanets S, Kaun C, Rychli K, Pfaffenberger S, Kastl SP, Hohensinner PJ, Rega G, Katsaros KM, Afonyushkin T, Bochkov VN, Paireder M, Huk I, Maurer G, Huber K, Wojta J. Oncostatin M-enhanced vascular endothelial growth factor expression in human vascular smooth muscle cells involves PI3K-, p38 MAPK-, Erk1/2- and STAT1/STAT3-dependent pathways and is attenuated by interferon-γ. Basic Res Cardiol. 2011;106:217-31.

Demyanets S, Konya V, Kastl SP, Kaun C, Rauscher S, Niessner A, Pentz R,
Pfaffenberger S, Rychli K, Lemberger CE, de Martin R, Heinemann A, Huk I, Gröger M, Maurer G, Huber K, Wojta J. Interleukin-33 induces expression of adhesion molecules and inflammatory activation in human endothelial cells and in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2011;31:2080-9.

De Luca G, Bellandi F, Huber K, Noc M, Petronio AS, Arntz HR, Maioli M, Gabriel
HM, Zorman S, DE Carlo M, Rakowski T, Gyöngyösi M, Dudek D. Early glycoprotein IIb-IIIa inhibitors in primary angioplasty-abciximab long-term results (EGYPT-ALT) cooperation: individual patient's data meta-analysis. J Thromb Haemost. 2011;9:2361- 70.

Dietl W, Trescher K, Hohensinner P, Nagel F, Ma Y, Wolfsberger M, Plasenzotti R, Hoffmann-Sommergruber K, Wojta J, Bauer M, Podesser BK. SiNiTang – A
traditional chinese herbal remedy improves cardiac function post-MI. J Clinic
Experiment Cardiol. 2011:5-9.

Eschenhagen T, Force T, Ewer MS, de Keulenaer GW, Suter TM, Anker SD, Avkiran M, de Azambuja E, Balligand JL, Brutsaert DL, Condorelli G, Hansen A, Heymans S, Hill JA, Hirsch E, Hilfiker-Kleiner D, Janssens S, de Jong S, Neubauer G, Pieske B, Ponikowski P, Pirmohamed M, Rauchhaus M, Sawyer D, Sugden PH, Wojta J, Zannad F, Shah AM. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2011;13:1-10.

Farhan S, Jarai R, Tentzeris I, Freynhofer MK, Brozovic I, Vogel B, Kautzky-Willer A, Wascher T, Wojta J, Huber K. Admission proinsulin is associated with mortality in patients with admission hyperglycemia during acute coronary syndrome: results from a pilot observational study. Clin Chem. 2011;57:1456-60.

Freynhofer MK, Brozovic I, Bruno V, Farhan S, Vogel B, Jakl G, Willheim M, Hübl W, Wojta J, Huber K. Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events. Thromb Haemost. 2011;106:230-9.

Freynhofer MK, Bruno V, Jarai R, Gruber S, Höchtl T, Brozovic I, Farhan S, Wojta J, Huber K. Levels of von Willebrand factor and ADAMTS13 determine clinical outcome after cardioversion for atrial fibrillation. Thromb Haemost. 2011;105:435-43.

Freynhofer MK, Bruno V, Brozovic I, Grove EL, Kristensen SD, Willheim M, Hübl W, Huber K. Is increased platelet turnover responsible for low responsiveness to different thienopyridienes? A case report of recurrent stent thromboses. Thromb Haemost. 2011;106(1):182-4.

Goliasch G, Wiesbauer F, Grafl A, Ponweiser E, Blessberger H, Tentzeris I, Wojta J, Schillinger M, Huber K, Maurer G, Mannhalter C, Sunder-Plassmann R. The effect of p22-PHOX (CYBA) polymorphisms on premature coronary artery disease (<40 years of age). Thromb Haemost. 2011;105:529-34.

Goliasch G, Blessberger H, Azar D, Heinze G, Wojta J, Bieglmayer C, Wagner O, Schillinger M, Huber K, Maurer G, Haas M, Wiesbauer F. Markers of bone
metabolism in premature myocardial infarction (<40 years of age). Bone.
2011;48:622-6.

Gyöngyösi M, Hemetsberger R, Wolbank S, Pichler V, Kaun C, Posa A, Petrasi Z, Petnehazy Ö, Hofer-Warbinek R, de Martin R, Gruber F, Benedek I, Benedek T, Kovacs I, Benedek I jr, Plass CA, Charwat S, Maurer G. Delayed recovery of
myocardial blood flow after intracoronary stem cell administration. Stem Cell Rev 2011;7:616–23.

Gyöngyösi M, Dib N. Diagnostic and prognostic value of 3D NOGA mapping in
ischemic heart disease. Nat Rev Cardiol. 2011;8:393-404.

Hemetsberger R, Posa A, Farhan S, Hemetsberger H, Redwan B, Pavo N, Pavo IJ, Plass CA, Petnehazy O, Petrasi Z, Huber K, Glogar D, Maurer G, Gyöngyösi M. Drug-eluting introducer sheath prevents local peripheral complications pre-clinical evaluation of nitric oxide-coated sheath. JACC Cardiovasc Interv. 2011;4:98-106.

Hohensinner PJ, Niessner A, Huber K, Weyand CM, Wojta J. Inflammation and
cardiac outcome. Curr Opin Infect Dis. 2011;24:259-64.

Höchtl T, Farhan S, Wojta J, Huber K. New anticoagulant agents in acute coronary syndromes. Heart. 2011;97:244-52.

Hoke M, Schillinger M, Zorn G, Wonnerth A, Amighi J, Mlekusch W, Speidl W, Maurer G, Koppensteiner R, Minar E, Wojta J, Niessner A. The prognostic impact of soluble apoptosis-stimulating fragment on mortality in patients with carotid atherosclerosis. Stroke. 2011;42:2465-70.

Holzinger C, Podesser BK, Lomoschitz F, Kassal H. Idiopathic pulmonary artery
aneurysm. J Card Surg. 2011;26:154-6.

Katsaros KM, Wiesbauer F, Speidl WS, Kastl SP, Huber K, Zorn G, Niessner A,
Glogar D, Maurer G, Wojta J. High soluble Fas and soluble Fas Ligand serum levels before stent implantation are protective against restenosis. Thromb Haemost. 2011;105:883-91.
 

Speidl WS, Kastl SP, Huber K, Wojta J. Complement in atherosclerosis - friend or foe? J Thromb Haemost. 2011;9:428-40.

Kastrup J, Jorgensen E, Fuchs S, Nikol S, Botker HE, Gyöngyösi M, Glogar D,
Kornowski R. A randomised, double-blind, placebo-controlled, multicentre study of the safety and efficacy of BIOBYPASS (AdGVVEGF121.10NH) gene therapy in patients with refractory advanced coronary artery disease: the NOVA trial. EuroIntervention. 2011;6:813-8.

Khorsand A, Gyöngyösi M, Sochor H, Maurer G, Karanikas G, Dudczak R, Schuster E, Porenta G, Graf S. Assessment of left ventricular volumes, ejection fraction and 17 mass. Comparison of model-based analysis of ECG-gated (99m)Tc-SPECT and 18FFDG- PET. Nuklearmedizin. 2011;50(1):9-14.

Lichtenauer M, Mildner M, Hoetzenecker K, Zimmermann M, Podesser BK, Sipos W, Berenyi E, Dworschak M, Tschachler E, Gyongyosi M, Ankersmit HJ. Secretome of apoptotic peripheral blood cells (APOSEC) confers cytoprotection to cardiomyocytes and inhibits tissue remodelling after acute myocardial infarction: a preclinical study. Basic Res Cardiol. 2011;106:1283–97.

Lichtenauer M, Mildner M, Baumgartner A, Hasun M, Werba G, Beer L, Altmann P, Roth G, Gyongyosi M, Podesser BK, Ankersmit HJ. Intravenous and
intramyocardial injection of apoptotic white blood cell suspensions prevents
ventricular remodelling by increasing elastin expression in cardiac scar tissue after myocardial infarction. Basic Res Cardiol. 2011;106:645-55.

Podesser BK. The old and multimorbid patient- a challenge in cardiac surgery and cardiology. Eur Surg. 2011;43:62.

Podesser BK. The ageing population- a challenge for cardiovascular surgery. Eur Surg. 2011;43:63-8.

Reis RL, Vienken J, Schima H, Wagner W, Tominaga R. Welcome to the European Society for Artificial Organs-International Federation for Artificial Organs joint congress in Porto, Portugal. Artif Organs. 2011;35:838-9.

Richter B, Gwechenberger M, Socas A, Zorn G, Albinni S, Marx M, Wolf F, Bergler- Klein J, Loewe C, Bieglmayer C, Binder T, Wojta J, Gössinger HD. Time course of markers of tissue repair after ablation of atrial fibrillation and their relation to left atrial structural changes and clinical ablation outcome. Int J Cardiol. 2011;152:231-6.

Rieder E, Stoiber M, Scheikl V, Poglitsch M, Dal Borgo A, Prager G, Schima H. Mesh fixation in laparoscopic incisional hernia repair: glue fixation provides attachment strength similar to absorbable tacks but differs substantially in different meshes. J Am Coll Surg. 2011;212:80-6.

Rychli K, Richter B, Hohensinner PJ, Mahdy Ali K, Neuhold S, Zorn G, Berger R,
Mörtl D, Huber K, Pacher R, Wojta J, Niessner A, Hülsmann M. Hepatocyte growth factor is a strong predictor of mortality in patients with advanced heart failure. Heart. 2011;97:1158-63.

Schmidt WM, Mitterer G, Podesser BK. Gene expression profiles characterizing the progression of heart failure in patients with aortic valve stenosis. Eur Surg.
2011;43:110-9.

Schwarzmaier-D'Assie A, Nyolczas N, Hemetsberger R, Strehblow C, Matiasek J, Farhan S, Petrasi Z, Huber K, Wojta J, Glogar D, Plass C, Gyöngyösi M, Karnik R. Comparison of short- and long-term results of drug-eluting vs. bare metal stenting in the porcine internal carotid artery. J Endovasc Ther. 2011;18:547-58.

Speidl WS, Kastl SP, Hutter R, Katsaros KM, Kaun C, Bauriedel G, Maurer G, Huber K, Badimon JJ, Wojta J. The complement component C5a is present in human coronary lesions in vivo and induces the expression of MMP-1 and MMP-9 in human macrophages in vitro. FASEB J. 2011;25:35-44.

Tentzeris I, Jarai R, Farhan S, Perkmann T, Schwarz MA, Jakl G, Wojta J, Huber K. Complementary role of copeptin and high-sensitivity troponin in predicting outcome in patients with stable chronic heart failure. Eur J Heart Fail. 2011;13:726-33.

Tentzeris I, Siller-Matula J, Farhan S, Jarai R, Wojta J, Huber K. Platelet function
variability and non-genetic causes. Thromb Haemost. 2011;105 Suppl 1:S60-6.

Tentzeris I, Jarai R, Farhan S, Wojta J, Schillinger M, Geppert A, Nürnberg M, Unger G, Huber K. Long-term outcome after drug-eluting stent implantation in comparison with bare metal stents: a single centre experience. Clin Res Cardiol. 2011;100:191- 200.

van der Spoel TI, Jansen of Lorkeers SJ, Agostoni P, van Belle E, Gyöngyösi M,
Sluijter JP, Cramer MJ, Doevendans PA, Chamuleau SA. Human relevance of preclinical studies in stem cell therapy: systematic review and meta-analysis of large animal models of ischaemic heart disease. Cardiovasc Res. 2011;91:649-58.

Weiss TW, Simak R, Kaun C, Rega G, Pflüger H, Maurer G, Huber K, Wojta J.
Oncostatin M and IL-6 induce u-PA and VEGF in prostate cancer cells and correlate in vivo. Anticancer Res. 2011;31:3273-8.

Weiss TW, Arnesen H, Troseid M, Kaun C, Hjerkinn EM, Huber K, Wojta J, Seljeflot I. Adipose tissue expression of interleukin-18 mRNA is elevated in subjects with metabolic syndrome and independently associated with fasting glucose. Wien Klin Wochenschr. 2011;123:650-4.

Yukhanyan L, Freynhofer MK, Siller-Matula J, Schrör K, Huber K. Genetic variability in response to clopidogrel therapy and its clinical implications. Thromb Haemost. 2011;105 Suppl 1:S55-9.

 

Publications 2010

Baudis S, Steyrer B, Pulka T, Wilhelm H, Weigel G, Bergmeister H, Stampfl J, Liska R. Photopolymerizable elastomers for vascular tissue regeneration.
Macromol. Symp. 2010;296:121-6.

Charwat S, Lang I, Dettke M, Graf S, Nyolczas N, Hemetsberger R, Zamini S,
Khorsand A, Sochor H, Maurer G, Glogar D, Gyöngyösi M. Effect of intramyocardial delivery of autologous bone marrow mononuclear stem cells on the regional myocardial perfusion. NOGA-guided subanalysis of the MYSTAR prospective randomised study. Thromb Haemost. 2010;103:564-71.

Cuisset T, Valgimigli M, Mudra H, Muller O, Wijns W, Huber K. Rationale and use of antiplatelet and antithrombotic drugs during cardiovascular interventions: May 2010 update. EuroIntervention. 2010;6:39-45.

Darra E, Rungatscher A, Carcereri de Prati A, Podesser BK, Faggian G, Scarabelli T, Mazzucco A, Hallström S, Suzuki H. Dual modulation of nitric oxide production in the heart during ischaemia/reperfusion injury and inflammation. Thromb Haemost. 2010;104:200-6.

De Luca G, Gibson CM, Gyöngyösi M, Zeymer U, Dudek D, Arntz HR, Bellandi F,
Maioli M, Noc M, Zorman S, Gabriel HM, Emre A, Cutlip D, Rakowski T, Huber K,
van't Hof AW. Gender-related differences in outcome after ST-segment elevation
myocardial infarction treated by primary angioplasty and glycoprotein IIb-IIIa
inhibitors: insights from the EGYPT cooperation. J Thromb Thrombolysis.
2010;30:342-6.

De Luca G, Gibson CM, Bellandi F, Noc M, Maioli M, Zorman S, Zeymer U, Gabriel HM, Emre A, Cutlip D, Arntz HR, Dudek D, Rakowski T, Gyöngyösi M, Huber K, van't Hof AW. Impact of distal embolization on myocardial perfusion and survival among patients undergoing primary angioplasty with glycoprotein IIb-IIIa inhibitors: insights from the EGYPT cooperation. J Thromb Thrombolysis. 2010;30:23-8.

De Luca G, Gibson CM, Gyöngyösi M, Zeymer U, Dudek D, Arntz HR, Bellandi F,
Maioli M, Noc M, Zorman S, Gabriel HM, Emre A, Cutlip D, Rakowski T, Huber K,
van't Hof AW. Gender-related differences in outcome after ST-segment elevation
myocardial infarction treated by primary angioplasty and glycoprotein IIb-IIIa
inhibitors: insights from the EGYPT cooperation. J Thromb Thrombolysis.
2010;30:342-6.

De Luca G, Gibson CM, Bellandi F, Noc M, Maioli M, Zorman S, Zeymer U, Gabriel HM, Emre A, Cutlip D, Arntz HR, Dudek D, Rakowski T, Gyongyosi M, Huber K, van't Hof AW. Impact of distal embolization on myocardial perfusion and survival among patients undergoing primary angioplasty with glycoprotein IIb-IIIa inhibitors: insights from the EGYPT cooperation. J Thromb Thrombolysis. 2010;30:23-8. PubMed PMID: 19921103.

Dörler J, Alber HF, Altenberger J, Bonner G, Benzer W, Grimm G, Huber K,
Kaltenbach L, Pfeiffer KP, Schuchlenz H, Siostrzonek P, Zenker G, Pachinger O,
Weidinger F; Austrian Acute PCI Investigators. Primary percutaneous intervention of ST-elevation myocardial infarction in Austria: Results from the Austrian acute PCI registry 2005-2007. Wien Klin Wochenschr. 2010;122:220-8.

Farhan S, Höchtl T, Wojta J, Huber K. Diabetic specific aspects in antithrombotic therapy in patients with coronary artery disease. Minerva Med. 2010;101:239-53.

Farhan S, Höchtl T, Kautzky-Willer A, Wojta J, Huber K. Antithrombotic therapy in
patients with coronary artery disease and with type 2 diabetes mellitus. Wien Med Wochenschr. 2010;160:30-8.

Farhan S, Höchtl T, Wojta J, Huber K. Diabetic specific aspects in antithrombotic therapy in patients with coronary artery disease. Minerva Med. 2010;101:239-53.

Farhan S, Höchtl T, Kautzky-Willer A, Wojta J, Huber K. Antithrombotic therapy in
patients with coronary artery disease and with type 2 diabetes mellitus. Wien Med Wochenschr. 2010;160:30-8.

Grasl C, Bergmeister H, Stoiber M, Schima H, Weigel G. Electrospun polyurethane vascular grafts: in vitro mechanical behavior and endothelial adhesion molecule expression. J Biomed Mater Res A. 2010;93:716-23.

Gyöngyösi M, Posa A, Pavo N, Hemetsberger R, Kvakan H, Steiner-Böker S, Petrasi Z, Manczur F, Pavo IJ, Edes IF, Wojta J, Glogar D, Huber K. Differential effect of ischaemic preconditioning on mobilisation and recruitment of haematopoietic and mesenchymal stem cells in porcine myocardial ischaemia-reperfusion. Thromb Haemost. 2010;104:376-84.

Gyöngyösi M, Hemetsberger R, Wolbank S, Kaun C, Posa A, Marian T, Balkay L,
Emri M, Galuska L, Mikecz P, Petrasi Z, Charwat S, Hemetsberger H, Blanco J,
Maurer G. Imaging the migration of therapeutically delivered cardiac stem cells.
JACC Cardiovasc Imaging. 2010;3:772-5.

Gyöngyösi M, Hemetsberger R, Posa A, Charwat S, Pavo N, Petnehazy O, Petrasi Z, Pavo IJ, Hemetsberger H, Benedek I, Benedek T, Benedek I Jr, Kovacs I, Kaun C, Maurer G. Hypoxia-inducible factor 1-alpha release after intracoronary versus intramyocardial stem cell therapy in myocardial infarction. J Cardiovasc Transl Res. 2010;3:114-21.

Gyöngyösi M, Posa A, Pavo N, Hemetsberger R, Kvakan H, Steiner-Böker S, Petrosi Z, Manczur F, Pavo IJ, Edes IF, Wojta J, Glogar D, Huber K. Differential effect of ischaemic preconditioning on mobilisation and recruitment of haematopoietic and mesenchymal stem cells in porcine myocardial ischaemia-reperfusion. Thromb Haemost. 2010;104:376-84. 29.

Hallström S, Podesser BK. The endothelium as target for interventions. In New
solutions for the heart- an update in advanced perioperative protection by Podesser BK, Chambers DK, eds; pp 145-165; Springer Wien New York 2010

Hasun M, Trescher K, Baumgartner A, Dietl W, Wolfsberger M, Hallström S,
Podesser BK. The new HTK-N46B cardioplegic solution provides superior protection during ischemia/reperfusion of the failing heart. AnnThoracic Surg 2010 submitted

Hohensinner PJ, Rychli K, Zorn G, Hülsmann M, Berger R, Mörtl D, Richter B,
Huber K, Wojta J, Pacher R, Niessner A. Macrophage-modulating cytokines predict adverse outcome in heart failure. Thromb Haemost. 2010;103:435-41.

Hohensinner PJ, Rychli K, Zorn G, Hülsmann M, Berger R, Mörtl D, Richter B,
Huber K, Wojta J, Pacher R, Niessner A. Macrophage-modulating cytokines
predictadverse outcome in heart failure. Thromb Haemost. 2010;103:435-41.

Huber K, Goldstein P, Danchin N, Fox KA. Network models for large cities: the
European experience. Heart. 2010;96:164-9.

Huber K. Genetic variability in response to clopidogrel therapy: clinical implications. Eur Heart J. 2010;31:2974-6.

Huber K, Holmes DR Jr, van 't Hof AW, Montalescot G, Aylward PE, Betriu GA,
Widimsky P, Westerhout CM, Granger CB, Armstrong PW. Use of glycoprotein
IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from
theAPEX-AMI trial. Eur Heart J. 2010;31:1708-16.

Jarai R, Huber K, Bogaerts K, Sinnaeve PR, Ezekowitz J, Ross AM, Zeymer U,
Armstrong PW, Van de Werf FJ; ASSENT-4 PCI investigators. Prediction
ofcardiogenic shock using plasma B-type natriuretic peptide and the Nterminalfragment of its pro-hormone [corrected] concentrations in ST elevation myocardial infarction: an analysis from the ASSENT-4 Percutaneous Coronary Intervention Trial. Crit Care Med. 2010;38:1793-801.

Jarai R, Huber K, Bogaerts K, Droogne W, Ezekowitz J, Granger CB, Sinnaeve PR, Ross AM, Zeymer U, Armstrong PW, Van de Werf FJ; ASSENT IV-PCI
investigators. Plasma N-terminal fragment of the prohormone B-type natriuretic
peptideconcentrations in relation to time to treatment and Thrombolysis in Myocardial Infarction (TIMI) flow: a substudy of the Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENTIV-PCI) trial. Am Heart J. 2010;159:131-40.

Karch R, Neumann F, Ullrich R, Heinze G, Neumüller J, Podesser BK, Neumann M. Methods from the theory of random heterogeneous media for quantifying myocardial morphology in normal and dilated hearts. Ann Biomed Eng 2010;38:308-18.

Katsaros KM, Kastl SP, Zorn G, Maurer G, Wojta J, Huber K, Christ G, Speidl WS. Increased restenosis rate after implantation of drug-eluting stents in patients with elevated serum activity of matrix metalloproteinase-2 and -9. JACC Cardiovasc Interv. 2010;3:90-7.

Leonardi S, Rao SV, Harrington RA, Bhatt DL, Gibson CM, Roe MT, Kochman J,
Huber K, Zeymer U, Madan M, Gretler DD, McClure MW, Paynter GE, Thompson
V, Welsh RC. Rationale and design of the randomized, double-blind trial testing
INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)- receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). Am Heart J. 2010;160:65-72.

Lip GY, Huber K, Andreotti F, Arnesen H, Airaksinen JK, Cuisset T, Kirchhof P,
Marv?n F; Consensus Document of European Society of Cardiology Working Group on Thrombosis. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Groupon Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and theEuropean Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2010;31:1311-8.

Lip GY, Huber K, Andreotti F, Arnesen H, Airaksinen KJ, Cuisset T, Kirchhof P,
Marin F; European Society of Cardiology Working Group on Thrombosis.
Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Thromb Haemost. 2010;103:13-28.

Katsaros KM, Kastl SP, Zorn G, Maurer G, Wojta J, Huber K, Christ G, Speidl WS. Increased restenosis rate after implantation of drug-eluting stents in patients with elevated serum activity of matrix metalloproteinase-2 and -9. JACC Cardiovasc Interv. 2010;3:90-7.

Moscato F, Arabia M, Colacino FM, Naiyanetr P, Danieli GA, Schima H. Left
ventricle afterload impedance control by an axial flow ventricular assist device: a potential tool for ventricular recovery. Artif Organs. 2010 Sep;34(9):736-44.

Naiyanetr P, Moscato F, Vollkron M, Zimpfer D, Wieselthaler G, Schima H.
Continuous assessment of cardiac function during rotary blood pump support: a contractility index derived from pump flow. J Heart Lung Transplant. 2010
Jan;29(1):37-44.

Oskolkova OV, Afonyushkin T, Preinerstorfer B, Bicker W, von Schlieffen E, Hainzl E, Demyanets S, Schabbauer G, Lindner W, Tselepis AD, Wojta J, Binder BR, Bochkov VN. Oxidized phospholipids are more potent antagonists of
lipopolysaccharide than inducers of inflammation. J Immunol. 2010;185:7706-12.

Plass CA, Podesser BK, Prusa AM. Effect of blower-mister devices of vasoreactivity of coronary artery bypass grafts. J Thorac Cardiovasc Surg. 2010;140:923-7.

Podesser BK, Chambers DJ, eds; New solutions for the heart- an update in advanced perioperative protection. Springer Wien New York 2010

Podesser BK. The changing population: the surgeon’s challenge. In New solutions for the heart- an update in advanced perioperative protection by Podesser BK, Chambers DK, eds; pp 3-12; Springer Wien New York 2010

Podesser BK, Trescher K, Dietl W. Protection of the failing heart. In New solutions for the heart- an update in advanced perioperative protection by Podesser BK. Chambers DK, eds; pp 109-130; Springer Wien New York 2010

Pomper G, Trescher K, Santer D, Hasun M, Baumgartner A, Adelmann K, Inci M,
Dietl W, Zuckermann AO, Podesser BK. Introducing a mouse model of brain death. J Neurosci Methods. 2010;192:70-4.

Posa A, Nyolczas N, Hemetsberger R, Pavo N, Petnehazy O, Petrasi Z, Sangiorgi G, Gyöngyösi M. Optimization of drug-eluting balloon use for safety and efficacy: evaluation of the 2nd generation paclitaxel-eluting DIOR-balloon in porcine coronary arteries. Catheter Cardiovasc Interv. 2010;76:395-403.

Posa A, Pavo N, Hemetsberger R, Csonka C, Csont T, Ferdinandy P, Petrasi Z, Varga C, Pavo IJ, Laszlo F Jr, Huber K, Gyöngyösi M. Protective effect of ischaemic preconditioning on ischaemia/reperfusion-induced microvascular obstruction determined by on-line measurements of coronary pressure and blood flow in pigs. Thromb Haemost. 2010;103:450-60.

Posa A, Pavo N, Hemetsberger R, Csonka C, Csont T, Ferdinandy P, Petrosi Z, Varga C, Pavo IJ, Laszlo F Jr, Huber K, Gyöngyösi M. Protective effect ofischaemic preconditioning on ischaemia/reperfusion-induced microvascular obstruction determined by on-line measurements of coronary pressure and blood flow in pigs. Thromb Haemost. 2010;103:450-60.

Richter B, Rychli K, Hohensinner PJ, Berger R, Mörtl D, Neuhold S, Zorn G, Huber K, Maurer G, Wojta J, Pacher R, Hülsmann M, Niessner A. Differences in the predictive value of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in advanced ischemic and non-ischemic heart failure. Atherosclerosis. 2010;213:545-8.

Richter B, Rychli K, Hohensinner PJ, Berger R, Mörtl D, Neuhold S, Zorn G, Huber K, Maurer G, Wojta J, Pacher R, Hülsmann M, Niessner A. Differences in the predictive value of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in advanced ischemic and non-ischemic heart failure. Atherosclerosis. 2010;213:545-8.

Rieder E, Stoiber M, Scheikl V, Poglitsch M, Dal Borgo A, Prager G, Schima H.
Mesh fixation in laparoscopic incisional hernia repair: glue fixation provides
attachment strength similar to absorbable tacks but differs substantially in different meshes. J Am Coll Surg. 2011 Jan;212(1):80-6. Epub 2010 Oct 29.

Rychli K, Niessner A, Hohensinner PJ, Mahdy Ali K, Kaun C, Neuhold S, Zorn G,
Richter B, Hülsmann M, Berger R, Mörtl D, Huber K, Maurer G, Pacher R, Wojta J. Prognostic value of pigment epithelium-derived factor in patients with advanced heart failure. Chest. 2010;138:656-64.

Rychli K, Kaun C, Hohensinner PJ, Dorfner AJ, Pfaffenberger S, Niessner A, Bauer M, Dietl W, Podesser BK, Maurer G, Huber K, Wojta J. The anti-angiogenic factor PEDF is present in the human heart and is regulated by anoxia in cardiac myocytes and fibroblasts. J Cell Mol Med. 2010;14:198-205.

Rychli K, Kaun C, Hohensinner PJ, Rega G, Pfaffenberger S, Vyskocil E, Breuss JM, Furnkranz A, Uhrin P, Zaujec J, Niessner A, Maurer G, Huber K, Wojta J. The
inflammatory mediator oncostatin M induces angiopoietin 2 expression in endothelial cells in vitro and in vivo. J Thromb Haemost. 2010 ;8:596-604.

Rychli K, Kaun C, Hohensinner PJ, Dorfner AJ, Pfaffenberger S, Niessner A, Bauer M, Dietl W, Podesser BK, Maurer G, Huber K, Wojta J. The anti-angiogenic factor PEDF is present in the human heart and is regulated by anoxia in cardiac myocytes and fibroblasts. J Cell Mol Med. 2010;14:198-205.

Rychli K, Niessner A, Hohensinner PJ, Mahdy Ali K, Kaun C, Neuhold S, Zorn G,
Richter B, Hülsmann M, Berger R, Mörtl D, Huber K, Maurer G, Pacher R, Wojta J. Prognostic value of pigment epithelium-derived factor in patients with advanced heart failure. Chest. 2010;138:656-64.

Rychli K, Kaun C, Hohensinner PJ, Rega G, Pfaffenberger S, Vyskocil E, Breuss JM, Furnkranz A, Uhrin P, Zaujec J, Niessner A, Maurer G, Huber K, Wojta J. The
inflammatory mediator oncostatin M induces angiopoietin 2 expression in endothelial cells in vitro and in vivo. J Thromb Haemost. 2010 ;8:596-604.

Saely CH, Aczel S, Koch L, Schmid F, Marte T, Huber K, Drexel H. Diabetes as a
coronary artery disease risk equivalent: before a change of paradigm? Eur J
Cardiovasc Prev Rehabil. 2010;17:94-9.

Schulz S, Birkmeier KA, Ndrepepa G, Moshage W, Dotzer F, Huber K, DirschingerJ, Seyfarth M, Schömig A, Kastrati A, Mehilli J. One-year clinical outcomes with abciximab in acute myocardial infarction: results of the BRAVE-3 randomized trial. Clin Res Cardiol. 2010;99:795-802.

Siller-Matula JM, Jilma B, Schrör K, Christ G, Huber K. Effect of proton pump
inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis. J Thromb Haemost. 2010;8:2624-41.

Siller-Matula JM, Huber K, Christ G, Schrör K, Kubica J, Herkner H, Jilma B.
Impact of clopidogrel loading dose on clinical outcome in patients undergoing
percutaneous coronary intervention: a systematic review and meta-analysis. Heart. 2011;97:98-105.

Siller-Matula JM, Tentzeris I, Vogel B, Schacherl S, Jarai R, Geppert A, Unger G,
Huber K. Tacrolimus-eluting carbon-coated stents versus sirolimus-eluting stents for prevention of symptom-driven clinical end points. Clin Res Cardiol. 2010;99:645-50.

Siller-Matula JM, Christ G, Lang IM, Delle-Karth G, Huber K, Jilma B. Multiple
electrode aggregometry predicts stent thrombosis better than the vasodilatorstimulated phosphoprotein phosphorylation assay. J Thromb Haemost. 2010;8:351-9.

Speidl WS, Kastl SP, Huber K, Wojta J. Complement in atherosclerosis - friend
or foe? J Thromb Haemost. 2010, in press

Speidl WS, Katsaros KM, Kastl SP, Zorn G, Huber K, Maurer G, Wojta J, Christ G. Coronary late lumen loss of drug eluting stents is associated with increased serum levels of the complement components C3a and C5a. Atherosclerosis. 2010;208:285-9.

Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous Cardiovascular Interventions (EAPCI), Kolh P, Wijns W, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, Huber K, James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, Pirlet C, Pomar JL, Reifart N, Ribichini FL, Schalij MJ, Sergeant P, Serruys PW, Silber S, Sousa Uva M, Taggart D. Guidelines on myocardial revascularization. Eur J Cardiothorac Surg. 2010;38 Suppl:S1-S52.

Tentzeris I, Jarai R, Farhan S, Brozovic I, Smetana P, Geppert A, Wojta J, Siller-
Matula J, Huber K. Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation. Thromb Haemost. 2010;104:1211-8.

Tentzeris I, Jarai R, Farhan S, Brozovic I, Smetana P, Geppert A, Wojta J, Siller-
Matula J, Huber K. Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation. Thromb Haemost. 2010;104:1211-8.

Thygesen K, Mair J, Katus H, Plebani M, Venge P, Collinson P, Lindahl B, Giannitsis E, Hasin Y, Galvani M, Tubaro M, Alpert JS, Biasucci LM, Koenig W, Mueller C, Huber K, Hamm C, Jaffe AS; Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. Recommendations for the use of cardiac troponin measurement in acute cardiac care. Eur Heart J. 2010;31:2197-204. Epub 2010 Aug 3. PubMed PMID: 20685679.

Widimsky P, Wijns W, Fajadet J, de Belder M, Knot J, Aaberge L, Andrikopoulos G, Baz JA, Betriu A, Claeys M, Danchin N, Djambazov S, Erne P, Hartikainen J, Huber K, Kala P, Klinceva M, Kristensen SD, Ludman P, Ferre JM, Merkely B, Milicic D, Morais J, Noc M, Opolski G, Ostojic M, Radovanovic D, De Servi S, Stenestrand U, Studencan M, Tubaro M, Vasiljevic Z, Weidinger F, Witkowski A, Zeymer U; European Association for Percutaneous Cardiovascular Interventions. Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. Eur Heart J. 2010;31:943-57.

Wöhrle J, Desaga M, Metzger C, Huber K, Suryapranata H, Guetta V, Guagliumi G, Witzenbichler B, Parise H, Mehran R, Stone GW. Impact of transfer for primary percutaneous coronary intervention on survival and clinical outcomes (from the HORIZONS-AMI Trial). Am J Cardiol. 2010;106:1218-24.

 

Publications 2009

ACTIVE Investigators, Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M,
Chrolavicius S, Yusuf S. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009;360:2066-78.

Alfonso F, Ambrosio G, Pinto FJ, Van der Wall EE, Kondili A, Nibouche D,
Adamyan K, Huber K, Ector H, Masic I, Tarnovska R, Ivanusa M, Stanek V,
Videbaek J, Hamed M, Laucevicius A, Mustonen P, Artigou JY, Cohen A, Rogava M, Böhm M, Fleck E, Heusch G, Klawki R, Vardas P, Stefanadis C, Tenczer J, Chiariello M, Elias J, Benjelloun H, Rodevand O, Kulakowski P, Apetrei E, Lusov VA, Oganov Ankersmit HJ, Hoetzenecker K, Dietl W, Soleiman A, Horvat R, Wolfsberger M, Gerner C, Hacker S, Mildner M, Moser B, Lichtenauer M, Podesser BK. Irradiated cultured apoptotic peripheral blood mononuclear cells regenerate infarcted myocardium. Eur J Clin Invest. 2009;39:445-56

APPRAISE Steering Committee and Investigators, Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M, Fox KA, Goodman SG, Harrington RA, Huber K, Husted S, Lewis BS, Lopez-Sendon J, Mohan P, Montalescot G, Ruda M, Ruzyllo W, Verheugt F, Wallentin L. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009;119:2877-85.

Atar D, Petzelbauer P, Schwitter J, Huber K, Rensing B, Kasprzak JD, Butter C,
GripL, Hansen PR, Süselbeck T, Clemmensen PM, Marin-Galiano M, Geudelin B, Buser PT; F.I.R.E. Investigators. Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial. J Am Coll Cardiol. 2009;53:720-9.

BARI 2D Study Group, Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF,
MacGregor JM, Orchard TJ, Chaitman BR, Genuth SM, Goldberg SH, Hlatky MA,
Jones TL, Molitch ME, Nesto RW, Sako EY, Sobel BE. A randomized trial of
therapies for type 2 diabetes and coronary artery disease. N Engl J Med.
2009;360:2503-15.

Baudis S, Heller C, Liska R, Stampfl J, Bergmeister H, Weigel G. (Meth)acrylatebased photoelastomers as tailored biomaterials for artificial vascular grafts. J Polym Sci Part A: Polym Chem 2009;47:2664-76.

Berger JS, Roe MT, Gibson CM, Kilaru R, Green CL, Melton L, Blankenship JD,
Metzger DC, Granger CB, Gretler DD, Grines CL, Huber K, Zeymer U, Buszman P, Harrington RA, Armstrong PW. Safety and feasibility of adjunctive antiplatelet
therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial. Am Heart J. 2009;158:998-1004.

Camenzind E, Wijns W, Mauri L, Boersma E, Parikh K, Kurowski V, Gao R, Bode C, Greenwood JP, Gershlick A, O'Neill W, Serruys PW, Jorissen B, Steg PG;
PROTECTSteering Committee and Investigators. Rationale and design of the Patient Related OuTcomes with Endeavor versus Cypher stenting Trial (PROTECT): randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantation. Am Heart J. 2009;158:902-909.

Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R,
Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-51.

De Luca G, Gibson CM, Bellandi F, Noc M, Dudek D, Zeymer U, Arntz HR, Cutlip
D, Maioli M, Zorman S, Mesquita Gabriel H, Emre A, Rakowski T, Gyongyosi M,
Huber K, Van't Hof AW. Diabetes mellitus is associated with distal embolization,
impaired myocardial perfusion, and higher mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty and glycoprotein IIb-IIIa inhibitors. Atherosclerosis. 2009;207:181-5.

De Luca G, Michael Gibson C, Bellandi F, Murphy S, Maioli M, Noc M, Zeymer U,
Dudek D, Arntz HR, Zorman S, Gabriel HM, Emre A, Cutlip D, Rakowski T,
Gyongyosi M, Huber K, Van't Hof AW. Benefits of pharmacological facilitation with glycoprotein IIb-IIIa inhibitors in diabetic patients undergoing primary angioplasty for STEMI. A subanalysis of the EGYPT cooperation. J Thromb Thrombolysis. 2009;28:288-98.

De Luca G, Gibson CM, Huber K, Zeymer U, Dudek D, Cutlip D, Bellandi F, Noc M, Emre A, Zorman S, Gabriel HM, Maioli M, Rakowski T, Gyöngyösi M, Van't Hof
AW; EGYPT Cooperation. Association between advanced Killip class at presentation and impaired myocardial perfusion among patients with ST-segment elevation myocardial infarction treated with primary angioplasty and adjunctive glycoprotein IIb-IIIa inhibitors. Am Heart J. 2009;158:416-21.

De Luca G, Gibson CM, Huber K, Zeymer U, Dudek D, Cutlip D, Bellandi F, Noc M, Emre A, Zorman S, Gabriel HM, Maioli M, Rakowski T, Gyöngyösi M, Van't Hof
AW; EGYPT Cooperation. Association between advanced Killip class at presentation and impaired myocardial perfusion among patients with ST-segment elevation myocardial infarction treated with primary angioplasty and adjunctive glycoprotein IIb-IIIa inhibitors. Am Heart J. 2009;158:416-21.

De Luca G, Gibson CM, Bellandi F, Noc M, Dudek D, Zeymer U, Arntz HR, Cutlip
D, Maioli M, Zorman S, Mesquita Gabriel H, Emre A, Rakowski T, Gyongyosi M,
Huber K, Van't Hof AW. Diabetes mellitus is associated with distal embolization,
impaired myocardial perfusion, and higher mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty and glycoprotein IIb/IIIa-inhibitors. Atherosclerosis. 2009;207:181-5.

Farhan S, Hemetsberger R, Matiasek J, Strehblow C, Pavo N, Khorsand A, Petneházy O, Petrási Z, Kaider A, Glogar D, Huber K, Gyöngyösi M. Implantation of paclitaxelelutingstent impairs the vascular compliance of arteries in porcine coronary stenting model. Atherosclerosis 2009;202:144-51.

Geidl L, Zrunek P, Deckert Z, Zimpfer D, Sandner S, Wieselthaler G, Schima H.
Usability and safety of ventricular assist devices: human factors and design aspects. Artif Organs. 2009;33:691-5.

Giugliano RP, White JA, Bode C, Armstrong PW, Montalescot G, Lewis BS, van 't
Hof A, Berdan LG, Lee KL, Strony JT, Hildemann S, Veltri E, Van de Werf F,
Braunwald E, Harrington RA, Califf RM, Newby LK; EARLY ACS Investigators.
Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med. 2009;360:2176-90.

Gyöngyösi M, Hemetsberger R, Posa A, Charwat S, Pavo N, Petnehazy Ö, Petrasi Z, Pavo IJ, Hemetsberger H, Benedek I, Benedek T, Benedek I, Kovacs I, Kaun C, Maurer G. Hypoxia-Inducible Factor 1-Alpha Release After Intracoronary Versus Intramyocardial Stem Cell Therapy in Myocardial Infarction. J. Cardiovasc. Trans. Res. 2009; DOI 10.1007/s12265-009-9154-1

Gyöngyösi M, Christ G, Lang I, Kreiner G, Sochor H, Probst P, Neunteufl T, Badr-
Eslam R, Winkler S, Nyolczas N, Posa A, Leisch F, Karnik R, Siostrzonek P, Harb S, Heigert M, Zenker G, Benzer W, Bonner G, Kaider A, Glogar D; AUTAX
Investigators. 2-year results of the AUTAX (Austrian Multivessel TAXUS-Stent)
registry beyond the SYNTAX (synergy between percutaneous coronary intervention with TAXUS and cardiac surgery) study. JACC Cardiovasc Interv. 2009;2:718-27.

Gyöngyösi M, Lang I, Dettke M, Beran G, Graf S, Sochor H, Nyolczas N, Charwat S, Hemetsberger R, Christ G, Edes I, Balogh L, Krause KT, Jaquet K, Kuck KH,
Benedek I, Hintea T, Kiss R, Préda I, Kotevski V, Pejkov H, Zamini S, Khorsand A, Sodeck G, Kaider A, Maurer G, Glogar D. Combined delivery approach of bone marrow mononuclear stem cells early and late after myocardial infarction: the MYSTAR prospective, randomized study Nat Clin Pract Cardiovasc Med. 2009;6:70- 81.

Gyöngyösi M. Research Highlights. Regen Med. 2009;4:663-6.

Hanusch-Enserer U, Zorn G, Wojta J, Kopp CW, Prager R, Koenig W, Schillinger M, Roden M, Huber K. Non-conventional markers of atherosclerosis before and after gastric banding surgery. Eur Heart J. 2009;30:1516-24.

Hanusch-Enserer U, Zorn G, Wojta J, Kopp CW, Prager R, Koenig W, Schillinger M, Roden M, Huber K. Non-conventional markers of atherosclerosis before and after gastric banding surgery. Eur Heart J. 2009;30:1516-24.

Hohensinner PJ, Kaun C, Rychli K, Niessner A, Pfaffenberger S, Rega G, Furnkranz A, Uhrin P, Zaujec J, Afonyushkin T, Bochkov VN, Maurer G, Huber K, Wojta J. The inflammatory mediator oncostatin M induces stromal derived factor-1 in human adult cardiac cells. FASEB J. 2009;23:774-82.
Moscato F, Danieli GA, Schima H. Dynamic modeling and identification of an axial flow ventricular assist device. Int J Artif Organs. 2009;32:336-43.

Huber K, Yasothan U, Hamad B, Kirkpatrick P. Prasugrel. Nat Rev Drug Discov.
2009;8:449-50.

Jarai R, Kaun C, Weiss TW, Speidl WS, Rychli K, Maurer G, Huber K, Wojta J.
Human cardiac fibroblasts express B-type natriuretic peptide. Fluvastatin ameliorates its upregulation by interleukin-1alpha, tumor necrosis factor-alpha and transforming growth factor-beta. J Cell Mol Med. 2009;13:4415-21.

Jarai R, Kaun C, Weiss TW, Speidl WS, Rychli K, Maurer G, Huber K, Wojta J.
Human cardiac fibroblasts express B-type natriuretic peptide. Fluvastatin ameliorates its upregulation by interleukin-1alpha, tumor necrosis factor-alpha and transforming growth factor-beta. J Cell Mol Med. 2009;13:4415-21.

Jarai R, Fellner B, Haoula D, Jordanova N, Heinz G, Karth GD, Huber K, Geppert A. Early assessment of outcome in cardiogenic shock: relevance of plasma N-terminal pro-B-type natriuretic peptide and interleukin-6 levels. Crit Care Med. 2009;37:1837- 44.

Kastl SP, Speidl WS, Katsaros KM, Kaun C, Rega G, Assadian A, Hagmueller GW, Hoeth M, de Martin R, Ma Y, Maurer G, Huber K, Wojta J. Thrombin induces the expression of oncostatin M via AP-1 activation in human macrophages: a link between coagulation and inflammation. Blood. 2009;114:2812-8.

Kastl SP, Speidl WS, Katsaros KM, Kaun C, Rega G, Assadian A, Hagmueller GW, Hoeth M, de Martin R, Ma Y, Maurer G, Huber K, Wojta J. Thrombin induces the expression of oncostatin M via AP-1 activation in human macrophages: a link between coagulation and inflammation. Blood. 2009;114:2812-8.

Khorsand A, Gyöngyösi M, Graf S, Zamini S, Schuster E, Sochor H, Porenta G.
Assessment of left ventricular volume and ejection fraction: comparison of QGS and MBGS analyses of ECG-gated myocardial perfusion SPECT imaging. Nucl Med Commun. 2009;30:300-7.

Kuliczkowski W, Witkowski A, Polonski L, Watala C, Filipiak K, Budaj A, Golanski J, Sitkiewicz D, Pregowski J, Gorski J, Zembala M, Opolski G, Huber K, Arnesen H, Kristensen SD, De Caterina R. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of CardiovascularInterventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J. 2009;30:426-35.

Malik M, Hnatkova K, Schmidt A, Smetana P. Electrocardiographic QTc changes
due to Moxifloxacin infusion. J Clin Pharmacol. 2009;49:674-83.

Malik M, Hnatkova K, Schmidt A, Smetana P. Correction for QT/RR hysteresis in
the assessment of drug-induced QTc changes - Cardiac safety of Gadobutrol. Ann Noninvasive Electrocardiol 2009;14:242-50.

Mehilli J, Kastrati A, Schulz S, Früngel S, Nekolla SG, Moshage W, Dotzer F, Huber K, Pache J, Dirschinger J, Seyfarth M, Martinoff S, Schwaiger M, Schömig A; Bavarian Reperfusion Alternatives Evaluation-3 (BRAVE-3) Study Investigators. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial. Circulation. 2009;119:1933-40.

Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Wong SC, Nikolsky E, Gambone L, Vandertie L, Parise H, Dangas GD, Stone GW; HORIZONS-AMI Trial Investigators. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet. 2009;374:1149-59.

Mills P, Timmis A, Huber K, Ector H, Lancellotti P, Masic I, Ivanusa M, Antoniades L, Aschermann M, Laucevicius A, Mustonen P, Artigou JY, Vardas P, Stefanadis C, Chiarello M, Bolognese L, Ambrosio G, van der Wall EE, Kulakowski P, Pinto FJ, Apetrei E, Oganov RG, Kamensky G, Lüscher TF, Lerch R, Haouala H, Sansoy V, Shumakov V, Tajer CD, Lau CP, Marquez M, Krittayaphong R, Arai K, Alfonso F. The role of European national journals in education. Heart. 2009;95:

Niessner A, Hohensinner PJ, Rychli K, Neuhold S, Zorn G, Richter B, Hülsmann M, Berger R, Mörtl D, Huber K, Wojta J, Pacher R. Prognostic value of apoptosis markers in advanced heart failure patients. Eur Heart J. 2009;30:789-96.

Niessner A, Hohensinner PJ, Rychli K, Neuhold S, Zorn G, Richter B, Hülsmann M, Berger R, Mörtl D, Huber K, Wojta J, Pacher R. Prognostic value of apoptosis markers in advanced heart failure patients. Eur Heart J. 2009;30:789-96.

Nyolczas N, Charwat S, Posa A, Hemetsberger R, Pavo N, Hemetsberger H, Pavo IJ, Glogar D, Maurer G, Gyöngyösi M. Tracking the migration of cardially delivered therapeutic stem cells in vivo: state of the art. Regen Med. 2009;4:407-22.

Rychli K, Huber K, Wojta J. Pigment epithelium-derived factor (PEDF) as a
therapeutic target in cardiovascular disease. Expert Opin Ther Targets. 2009;13:1295-
302.

Pop-Busui R, Lu J, Lopes N, Jones TL; BARI 2D Investigators. Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort. J Peripher Nerv Syst. 2009;14:1-13.

Posa A, Pavo N, Hemetsberger R, Csonka C, Csont T, Ferdinandy P, Petrasi Z, Varga C, Pavo IJ, Laszlo F jr, Huber K, Gyöngyösi M. Protective Effect of Ischemic Preconditioning on Ischemia/Reperfusion Induced Microvascular Obstruction Determined by On-line Measurements of Coronary Pressure and Blood Flow in Pigs. Thromb Haemost 2009;103:450-60.

Rashba EJ, Lamas GA, Couderc JP, Hollist SM, Dzavik V, Ruzyllo W, Fridrich V,
Buller CE, Forman SA, Kufera JA, Carvalho AC, Hochman JS; OAT-EP
Investigators. Electrophysiological effects of late percutaneous coronary intervention for infarct-related coronary artery occlusion: the Occluded Artery Trial- Electrophysiological Mechanisms (OAT-EP). Circulation. 2009;119:779-87.

RG, Obradovic V, Kamensky G, Kenda MF, Höglund C, Lüscher TF, Lerch R,
Jokhadar M, Haouala H, Sansoy V, Shumakov V, Timmis A, Tajer CD, Coard K,
Hajar R, Lau CP, Chopra HK, Tabatabaei SA, Marquez MF, Samad A, Galeano J,
Doubell A, Kuo CT,Krittayaphong R, Arai K, Bacal F, Guzman L; Grupo de Trabajo de la SociedadEuropea de Cardiologia. European National Society cardiovascular journals. Background, rationale and mission statement of the "Editors' Club". Arch Cardiol Mex. 2009;79:157-64.

Ross AM, Huber K, Zeymer U, Armstrong PW, Granger CB, Goldstein P, Bogaerts K, Van de Werf F. The impact of place of enrollment and delay to reperfusion on 90-day post-infarction mortality in the ASSENT-4 PCI trial: assessment of the safety and efficacy of a new treatment strategy with percutaneous coronary intervention. JACC Cardiovasc Interv. 2009;2:925-30.

Rychli K, Huber K, Wojta J. Pigment epithelium-derived factor (PEDF) as a
therapeutic target in cardiovascular disease. Expert Opin Ther Targets. 2009;13:1295-302.

Schwartz GG, Olsson AG, Ballantyne CM, Barter PJ, Holme IM, Kallend D, Leiter
LA, Leitersdorf E, McMurray JJ, Shah PK, Tardif JC, Chaitman BR, Duttlinger-
Maddux R, Mathieson J; dal-OUTCOMES Committees and Investigators. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J. 2009;158:896-901.

Sinnaeve PR, Ezekowitz JA, Bogaerts K, Droogne W, Jarai R, Huber K, Granger CB, Desmet WJ, Armstrong PW, Van de Werf FJ; ASSENT-4 PCI Investigators.
Reperfusion before percutaneous coronary intervention in ST-elevation myocardial infarction patients is associated with lower N-terminal pro-brain natriuretic peptide levels during follow-up, irrespective of pre-treatment with full-dose fibrinolysis. Eur Heart J. 2009;30:2213-9.

Stoiber M, Grasl C, Pirker S, Raderer F, Schistek R, Huber L, Gittler P, Schima H. A passive magnetically and hydrodynamically suspended rotary blood pump. Artif Organs. 2009;33:250-7.

Stone GW, Lansky AJ, Pocock SJ, Gersh BJ, Dangas G, Wong SC, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Mäckel M, Ochala A, Kellock A, Parise H, Mehran R; HORIZONS-AMI Trial Investigators. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med. 2009;360:1946-59.

TRA*CER Executive and Steering Committees. The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale. Am Heart J. 2009;158:327-334.

Trescher K, Bauer M, Dietl W, Hallstroem S, Wick N, Wolfsberger M, Ulrich R,
Jürgens G, Wolner E, Podesser BK. Improved myocardial protection in the failing heart by selective endothelin-A receptor blockade. J Thorac Cardiovasc Surg 2009; 137:1005-11

Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V,Filippatos
G, Fox K, Huber K, Kastrati A, Rosengren A, Steg PG, Tubaro M, Verheugt F,
Weidinger F, Weis M; Task Force per il Trattamento dell'Infarto Miocardico Acuto
con; Sopraslivellamento del Tratto ST della Societa Europea di Cardiologia, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Silber S, Aguirre FV, Al-Attar N, Alegria E, Andreotti F, Benzer W, Breithardt O, Danchin N, Di Mario C, Dudek D, Gulba D, Halvorsen S, Kaufmann P, Kornowski R, Lip GY, Rutten F, Societa Europea di Cardiologia. Management of acute myocardial infarction in patients presenting with persistent STsegment elevation]. G Ital Cardiol. 2009;10:450-89.

Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, Filippatos , Fox K, Huber K, Kastrati A, Rosengren A, Steg PG, Tubaro M, Verheugt F, Weidinger F, Weis M. ESC guidelines on management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. Rev Esp Cardiol. 2009;62:293.

Voitl P, Vollkron M, Bergmeister H, Wieselthaler G, Schima H. Coronary
hemodynamics and myocardial oxygen consumption during support with rotary blood pumps. Artif Organs. 2009;33:77-80.

Voitl P, Vollkron M, Bergmeister H, Wieselthaler G, Schima H. Coronary
hemodynamics and myocardial oxygen consumption during support with rotary blood pumps. Artif Organs. 2009;33:77-80.

Waclavicek M, Stich N, Rappan I, Bergmeister H, Eibl MM. Analysis of the early
response to TSST-1 reveals Vbeta-unrestricted extravasation, compartmentalization of the response, and unresponsiveness but not anergy to TSST-1. J Leukoc Biol. 2009;85:44-54.

Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators, Freij A, Thorsen M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045- 57.

Wiesbauer F, Blessberger H, Goliasch G, Holy EW, Pfaffenberger S, Tentzeris I,
Maurer G, Huber K, Abdolvahab F, Sodeck G, Exner M, Wojta J, Schillinger M.
Elevated risk of myocardial infarction in very young immigrants from former
Yugoslavia. Eur J Epidemiol. 2009;24:691-6.

Wiesbauer F, Blessberger H, Goliasch G, Holy EW, Pfaffenberger S, Tentzeris I,
Maurer G, Huber K, Abdolvahab F, Sodeck G, Exner M, Wojta J, Schillinger M.
Elevated risk of myocardial infarction in very young immigrants from former
Yugoslavia. Eur J Epidemiol. 2009;24:691-6.

Wiesbauer F, Blessberger H, Azar D, Goliasch G, Wagner O, Gerhold L, Huber K, Widhalm K, Abdolvahab F, Sodeck G, Maurer G, Schillinger M. Familial-combined hyperlipidaemia in very young myocardial infarction survivors (< or =40 years of age). Eur Heart J. 2009;30:1073-9.

 

Publications 2008

Bastian F, Stelzmueller ME, Kratochwill K, Kasimir MT, Simon P, Weigel G. IgG deposition and activation of the classical complement pathway involvement in the activation of human granulocytes by decellularized porcine heart valve tissue. Biomaterials 2008; 29: 1824-1832.

Bauer, M., Podesser, B.K. Gender- and Sex-specific Differences in Ischemic Heart Failure, the Role of Estrogen. Gender Medicine 2008

Bauer, M., Dietl, W., Trescher, K., Gyöngyösi, M., Podesser, B.K.
Endothelin A-Receptor Blockade Diminishes Sex-Specific Differences in Post-MI Remodeling. Basic Res Cardiol 2008

Dietl, W., Mitterer, G., Thometich, B., Bauer, M., Trescher, K., Gyöngyösi,M., Kaun, C., Bittner, R., Schmidt, W., Podesser, B.K. Endothelin-A Receptor Blockade attenuates Tenascin-C Expression after Myocardial Infarction.
Cardiovascular Research 2008.

Hallström, S., Franz, M., Gasser, H., Vodrazka, M., Semsroth, S., Losert, U., Haisjakl, M., Podesser, B.K., Malinski, T. S-Nitroso Human Serum Albumin Reduces Ischemia/Reperfusion Injury in the Pig Heart after Unprotected Warm Ischemia. Cardiovasc Res. 2008 Feb 15;77(3):506-14.

S.P. Kastl, W.S. Speidl, C. Kaun, K.M. Katsaros, G. Rega, T. Afonyushkin, V.N. Bochkov, P. Valent, A. Assadian, G.W. Hagmueller, M. Hoeth, R. de Martin, Y. Ma, G. Maurer, K. Huber, J. Wojta: In human macrophages the complement component C5a induces the expression of oncostatin M via AP-1 activation. Arterioscler. Thromb. Vasc. Biol. 28: 498-503, 2008

K.M. Katsaros, S.P. Kastl, G. Zorn, K. Huber, G. Maurer, D. Glogar, J. Wojta, G. Christ, W.S. Speidl. Clopidogrel pretreatment abolishes increase of PAI-1 after coronary stent implantation. Thromb. Res. 2008

F. Moscato, G.A.Danieli, H. Schima: Hydrodynamic identification of an axial flow
ventricular device. Int. J. Artif. Organs 2008

P. Naiyanetr, M. Vollkron, D. Zimpfer, S. Sandner, G. Wieselthaler, H. Schima: Cardiac contractility index during axial flow left ventricular assist device support using left ventricular pressure relationship: a computer model and animal study. Int. J. Artif Organs 2008

P. Naiyanetr, M. Vollkron, D. Zimpfer, S. Sandner, G. Wieselthaler, H. Schima: Estimation of cardiac contractility during rotary blood pump support using an index derived from left ventricular pressure; IFMBE Transactions 2008, Proceedings of the MBEC08

Kastl SP, Speidl WS, Kaun C, Katsaros KM, Rega G, Afonyushkin T, Bochkov VN, Valent P, Assadian A, Hagmueller GW, Hoeth M, de Martin R, Ma Y, Maurer G, Huber K, Wojta J. In human macrophages the complement component C5a induces the expression of oncostatin M via AP-1 Activation. Arterioscler. Thromb. Vasc. Biol. 28: 498-503, 2008

Katsaros KM, Speidl WS, Kastl SP, Zorn G, Huber K, Maurer G, Glogar D, Wojta J, Christ G. Plasminogen activator inhibitor-1 predicts coronary in-stent restenosis of drug-eluting stents. J Thromb Haemost 2008; 6: 508–13.

Katsaros KM, Kastl SP, Zorn G, Huber K, Maurer G, Glogar D, Wojta J, Christ G, Speidl WS. Clopidogrel pretreatment abolishes increase of PAI-1 after coronary stent implantation Thromb. Res. 2008

Kolroser G, Kasimir MT, Eichmair E, Nigisch A, Simon P, Weigel G. Scanning electron microscopy and energy-dispersive X-ray microanalysis: a valuable tool for studying cell surface antigen expression on tissue engineered scaffolds Submitted to Tissue Engineering 2008.

Trescher, K., Bauer, M., Dietl, W., Hallström, S., Wick, N., Wolner, E., Podesser, B.K. Improved myocardial protection in the failing heart by selective endothelin-A receptor blockade. Journal of Thoracic and Cardiovascular Surgery 2008.
 

Publications 2007

Statins decrease TNF-alpha-induced osteoprotegerin production by endothelial cells and smooth muscle cells in vitro. Ben-Tal Cohen E, Hohensinner PJ, Kaun C, Maurer G, Huber K, Wojta J. Biochem Pharmacol. 2007 Jan 1;73(1):77-83.

The inflammatory cytokine oncostatin M induces PAI-1 in human vascular smooth muscle cells in vitro via PI 3-kinase and ERK1/2-dependent pathways.
Demyanets S, Kaun C, Rychli K, Rega G, Pfaffenberger S, Afonyushkin T, Bochkov VN, Maurer G, Huber K, Wojta J. Am J Physiol Heart Circ Physiol. 2007 Sep;293(3):H1962-8.

Antiplatelet drug induced isolated profound thrombocytopenia in interventional cardiology: a review based on individual case reports. Höchtl T, Pachinger L, Unger G, Geppert A, Wojta J, Harenberg J, Huber K. J Thromb Thrombolysis. 2007 Aug;24(1):59-64.

Macrophage colony stimulating factor expression in human cardiac cells is upregulated by tumor necrosis factor-alpha via an NF-kappaB dependent mechanism. Hohensinner PJ, Kaun C, Rychli K, Niessner A, Pfaffenberger S, Rega G, de Martin R, Maurer G, Ullrich R, Huber K, Wojta J.
J Thromb Haemost. 2007 Dec;5(12):2520-8.

Prediction of clinical outcome in patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) using the TIMI risk score extended by N-terminal pro-brain natriuretic peptide levels. Jarai R, Iordanova N, Jarai R, Jarai F, Raffetseder A, Woloszczuk W, Gyöngyösi M, Geyer G, Wojta J, Huber K.
Wien Klin Wochenschr. 2007;119(21-22):626-32.

Left ventricular pressure-volume loop analysis during continuous cardiac assist in acute animal trials.
Moscato F, Vollkron M, Bergmeister H, Wieselthaler G, Leonard E, Schima H.
Artif Organs. 2007 May;31(5):369-76.

Low high-density lipoprotein cholesterol predicts cardiovascular events after carotid stenting: a long-term survey.
Niessner A, Hofmann R, Kypta A, Steinwender C, Kerschner K, Kammler J, Leisch F, Huber K. J Thromb Haemost. 2007 May;5(5):950-4

Nitric oxide homeostasis as a target for drug additives to cardioplegia.
Podesser BK, Hallström S.
Br J Pharmacol. 2007 Aug;151(7):930-40. Epub 2007 May 8. Review.
PMID: 17486142

Unveiling gender differences in demand ischemia: a study in a rat model of genetic hypertension.
Podesser BK, Jain M, Ngoy S, Apstein CS, Eberli FR.
Eur J Cardiothorac Surg. 2007 Feb;31(2):298-304

Effect of continuous arterial blood flow in patients with rotary cardiac assist device on the washout of a stenosis wake in the carotid bifurcation: a computer simulation study.
Prosi M, Perktold K, Schima H.
J Biomech. 2007;40(10):2236-43.

Vascular endothelial growth factor is induced by the inflammatory cytokines interleukin-6 and oncostatin m in human adipose tissue in vitro and in murine adipose tissue in vivo.
Rega G, Kaun C, Demyanets S, Pfaffenberger S, Rychli K, Hohensinner PJ, Kastl SP, Speidl WS, Weiss TW, Breuss JM, Furnkranz A, Uhrin P, Zaujec J, Zilberfarb V, Frey M, Roehle R, Maurer G, Huber K, Wojta J.
Arterioscler Thromb Vasc Biol. 2007 Jul;27(7):1587-95.

Thienopyridines in cardiovascular disease: focus on clopidogrel resistance.
Siller-Matula J, Schrör K, Wojta J, Huber K.
Thromb Haemost. 2007 Mar;97(3):385-93. Review.

Premature compared with late onset of coronary artery disease: young patients show a severe defect in fibrinolytic response to venous occlusion.
Speidl WS, Nikfardjam M, Niessner A, Jordanova N, Zorn G, Maurer G, Schreiber W, Wojta J, Huber K.
Blood Coagul Fibrinolysis. 2007 Mar;18(2):165-71.

Mild hyperhomocysteinemia is associated with a decreased fibrinolytic activity in patients after ST-elevation myocardial infarction.
Speidl WS, Nikfardjam M, Niessner A, Zeiner A, Jordanova N, Zorn G, Maurer G, Schreiber W, Wojta J, Huber K.
Thromb Res. 2007;119(3):331-6.

Experimental validation of numerical simulations: a comparison of computational fluid dynamics and the oil film method.
Stoiber M, Grasl C, Pirker S, Huber L, Gittler P, Schima H.
Int J Artif Organs. 2007 Apr;30(4):363-8.

Suction events during left ventricular support and ventricular arrhythmias.
Vollkron M, Voitl P, Ta J, Wieselthaler G, Schima H.
J Heart Lung Transplant. 2007 Aug;26(8):819-25.

 

Publications 2006

Hydroxymethylglutaryl-coenzyme A reductase inhibitors induce apoptosis in human cardiac myocytes in vitro.
Demyanets S, Kaun C, Pfaffenberger S, Hohensinner PJ, Rega G, Pammer J, Maurer G, Huber K, Wojta J.
Biochem Pharmacol. 2006 Apr 28;71(9):1324-30.

Statins modulate expression of components of the plasminogen activator/plasmin system in human cardiac myocytes in vitro.
Demyanets S, Kaun C, Maurer G, Huber K, Wojta J.
J Thromb Haemost. 2006 Feb;4(2):476-9.

The estrogen metabolite 17beta-dihydroequilenin counteracts interleukin-1alpha induced expression of inflammatory mediators in human endothelial cells in vitro via NF-kappaB pathway.
Demyanets S, Pfaffenberger S, Kaun C, Rega G, Speidl WS, Kastl SP, Weiss TW, Hohensinner PJ, Dietrich W, Tschugguel W, Bochkov VN, Awad EM, Maurer G, Huber K, Wojta J.
Thromb Haemost. 2006 Jan;95(1):107-16.

Nitric oxide in cardiac transplantation.
Dietl W, Bauer M, Podesser BK.
Pharmacol Rep. 2006;58 Suppl:145-52. Review.

Plasma concentrations of interleukin-6, organ failure, vasopressor support, and successful coronary revascularization in predicting 30-day mortality of patients with cardiogenic shock complicating acute myocardial infarction.
Geppert A, Dorninger A, Delle-Karth G, Zorn G, Heinz G, Huber K.
Crit Care Med. 2006 Aug;34(8):2035-42.

Platelet activation and high tissue factor level predict acute stent thrombosis in pig coronary arteries: prothrombogenic response of drug-eluting or bare stent implantation within the first 24 hours.
Gyöngyösi M, Strehblow C, Sperker W, Hevesi A, Garamvölgyi R, Petrási Z, Pavo N, Ferdinandy P, Csonka C, Csont T, Sylvèn C, Declerck PJ, Pavo I Jr, Wojta J, Glogar D, Huber K.
Thromb Haemost. 2006 Aug;96(2):202-9.

Monocyte chemoattractant protein (MCP-1) is expressed in human cardiac cells and is differentially regulated by inflammatory mediators and hypoxia.
Hohensinner PJ, Kaun C, Rychli K, Ben-Tal Cohen E, Kastl SP, Demyanets S, Pfaffenberger S, Speidl WS, Rega G, Ullrich R, Maurer G, Huber K, Wojta J.
FEBS Lett. 2006 Jun 12;580(14):3532-8.

Implementation of guidelines improves the standard of care: the Viennese registry on reperfusion strategies in ST-elevation myocardial infarction (Vienna STEMI registry).
Kalla K, Christ G, Karnik R, Malzer R, Norman G, Prachar H, Schreiber W, Unger G, Glogar HD, Kaff A, Laggner AN, Maurer G, Mlczoch J, Slany J, Weber HS, Huber K; Vienna STEMI Registry Group.
Circulation. 2006 May 23;113(20):2398-405. Epub 2006 May 15.

The complement component C5a induces the expression of plasminogen activator inhibitor-1 in human macrophages via NF-kappaB activation.
Kastl SP, Speidl WS, Kaun C, Rega G, Assadian A, Weiss TW, Valent P, Hagmueller GW, Maurer G, Huber K, Wojta J.
J Thromb Haemost. 2006 Aug;4(8):1790-7.

Simvastatin suppresses endotoxin-induced upregulation of toll-like receptors 4 and 2 in vivo.
Niessner A, Steiner S, Speidl WS, Pleiner J, Seidinger D, Maurer G, Goronzy JJ, Weyand CM, Kopp CW, Huber K, Wolzt M, Wojta J.
Atherosclerosis. 2006 Dec;189(2):408-13.

Endurance training reduces circulating inflammatory markers in persons at risk of coronary events: impact on plaque stabilization?
Niessner A, Richter B, Penka M, Steiner S, Strasser B, Ziegler S, Heeb-Elze E, Zorn G, Leitner-Heinschink A, Niessner C, Wojta J, Huber K.
Atherosclerosis. 2006 May;186(1):160-5.

First clinical experience with an automatic control system for rotary blood pumps during ergometry and right-heart catheterization.
Schima H, Vollkron M, Jantsch U, Crevenna R, Roethy W, Benkowski R, Morello G, Quittan M, Hiesmayr M, Wieselthaler G.
J Heart Lung Transplant. 2006 Feb;25(2):167-73.

Inflammation and postinfarct remodeling: overexpression of IkappaB prevents ventricular dilation via increasing TIMP levels.
Trescher K, Bernecker O, Fellner B, Gyöngyösi M, Schäfer R, Aharinejad S, DeMartin R, Wolner E, Podesser BK.
Cardiovasc Res. 2006 Feb 15;69(3):746-54. Epub 2006 Jan 4.

No evidence for a direct role of Helicobacter pylori and Mycoplasma pneumoniae in carotid artery atherosclerosis.
Weiss TW, Kvakan H, Kaun C, Prager M, Speidl WS, Zorn G, Pfaffenberger S, Huk I, Maurer G, Huber K, Wojta J.
J Clin Pathol. 2006 Nov;59(11):1186-90.